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ABSTRACT 
THRESHOLD MODELS FOR GENOME-WIDE ASSOCIATION MAPPING OF 
FAMILIAL BREAST CANCER INCIDENCE IN HUMANS 
NASIR ELMESMARI 
2017 
Breast cancer is the second most fatal cancer in the world and one of the most highly 
harmful cancers from which people suffer. Breast cancer studies have been able to uncover 
some knowledge about genetic susceptibility for familial breast cancer in humans. Hence, 
determining genetic factors may potentially help track the disease, as well as discover the 
cancer in early stages, or perhaps before it starts. In addition, this may allow early 
determination of possible treatment strategies which will make it easier to prevent the 
disease. In this context, it is important to determine whether the heritability of breast cancer 
incidence is greater than zero, which can be investigated if there is a potential genetic 
component playing a role in the incidence of the disease. Traits with zero heritability are 
said to be completely subject to environmental factors, so genetics has no effect at all. 
Heritability is important because it indicates the extent of genetic variations which could 
provide a reason for the infection. In the case that heritability is found to be greater than 
zero, it is useful to estimate the single nucleotide polymorphism (SNP) effects, which may 
potentially determine the genes or the genomic regions that are associated with the 
incidence of breast cancer. 
This study used data for three families with BRCAx as exome sequences provided 
by the University of Nebraska Medical Center and the Institutional Review Boards of 
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Creighton University. Specifically, the data consisted of pedigree information for 167 
individuals from three families, including information on whether each person had breast 
cancer or not (binary trait, positive or negative). Genomic data was available for 22 
individuals among the 167. Theoretically, heritability as well as SNP effects can be 
estimated using a variety of approaches, but given the data available for this study, the best 
strategy was to combine both the pedigree-based data and the genomic data in one matrix. 
This matrix offers an advantage over other approaches that use only one of these datasets. 
The data was analyzed using a threshold model and Gibbs sampling algorithm to estimate 
the heritability of breast cancer incidence, as well as to predict SNP effects. The binary 
response variable for breast cancer incidence was modeled such that gender (2 levels) and 
family (3 levels) were the fixed effects. The effect of the subjects was the only random 
effect in the model. 
 The heritability estimate was approximately 28%, indicating that there is a 
considerable genetic component underlying the incidence of breast cancer. In addition, the 
Genome-Wide Association Study (GWAS) analysis revealed that breast cancer is a 
complex trait, possibly controlled by many genes. However, some areas on the genome 
(specifically, chromosomes 1, 2, 4, 8, 14 and 16) may include candidate genes associated 
with breast cancer incidence. These genes might be responsible for this type of cancer and 
play important roles in susceptibility for the disease. The 20 SNPs with highest effects 
explained more than 3.5 % of the genetic variance, which is a good indicator that their 
genes are associated with breast cancer. The results of this study open the door for more 
research on breast cancer incidence. Despite the limitations related to the small sample 
used, the results of this study could be considered a first step for future work and 
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investigation. Further studies using larger data sets may reveal more information on this 
complex trait.         
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 Introduction 
According to the World Health Organization (WHO), the number of patients who 
die from cancer has raised up from 8.2 million in 2012 to 8.8 million in 2015. This high 
number of deaths has been attributed to late diagnosis and lack of proper treatment. The 
delay of diagnosis occurs even in countries that have excellent health systems [1]. In the 
United States, the 2016 annual report noted 1,685,210 new cases of cancer diagnosed, as 
well as 595,690 cancer deaths [2]. 
Developing a cure for various cancers has been a worldwide initiative in the past 
two decades because it is considered to be one of the leading causes of death [3]. For 
instance, breast cancer is ranked the second deadliest cancer in the world. In order to 
appropriately determine cures or treatments for any disease, it is imperative that the cause 
is uncovered. Understanding a disease at the point of origin will also enable earlier 
diagnosis. Additionally, various types of cancer are more easily eradicated in the early 
stages. Some studies have indicated that heritability is a major contributing factor for the 
disease. Measuring heritability is, therefore, an important step in revealing the extent of 
the variation in response attributed to biological effect. Many breast cancer studies have 
been able to uncover the significance of genetic influences [4]. 
The history of heritability goes back to at least the 19th century. However, the 
ideas surrounding heritability estimates were developed by Wright (1920) [5]. He used 
the concept of heritability in his study on the coat color of guinea pigs [6]. This term is 
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significant because scientists use it to assess the interaction of genes and environment to 
determine the survivor species under the law of natural selection. Moreover, it is vital to 
estimating the potential for diseases in plants, animals and humans [7]. In a study 
conducted by Taylor (1975), he found a strong relationship between cancer and a 
predisposition due to exposure to ion radiation. Many patients showed extensive cell 
damage which led to breast cancer. In addition, the age of the patients did not have any 
role in causing cancer [8]. 
 Roberts et al (1999) used a mixed model based on lognormal distributions to 
estimate the heritability of breast cancer [9]. Two studies of twins were used to evaluate 
this hypothesis, showing that the density of tissues in mammography at a given age had 
high heritability [10]. Moreover, other researchers have stated that the variance and 
covariance component models are useful in evaluating the heritability of breast density 
measures, serum sex-hormone levels, and volumetric mammographic density [11, 12].  
 The most common method used to estimate heritability is the linear mixed effect 
model (LME). Speed et al (2012) used an innovative approach GWAS to estimate 
heritability, discovering that kinship coefficients can be computed from genome-wide 
SNP genotypes, rather than from a known pedigree [13]. Cheng et al (2014) proposed a 
new inferential model that was able to evaluate the heritability coefficient [14]. 
Heckerman et al (2016) used a linear mixed effect model for the genomic random effect 
by using the kinship matrix (identity-by-descent estimates) from accurately phased 
genome-wide data [15]. Fong et al (2010) presented a GWAS Analyzer; this helps to 
limit a huge amount of phenotypic and genotypic data to predict the candidate gene that 
causes the severity of a disease by using SNPs [16]. 
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 In animal science, Misztal et al (2009) proposed a methodology to incorporate 
genomic information in addition to pedigree and phenotypic information, in one matrix 
[17]. A year later, Aguilar et al (2010) used this matrix to predict breeding value [18]. El-
Dien et al (2016) presented a study in plant science as a first attempt to replace pedigree 
information (numerator matrix) with the genomic relationship matrix (G-matrix). They 
were then able to calculate more realistic variance components and heritability estimates 
for forest trees [19]. The use of animal and plant information may help us better 
understand genetic structure in humans as well. 
 Based on previous GWAS studies, approximately 100 common breast cancer 
susceptibility alleles have been identified [20]. Genetic studies on breast cancer have 
been conducted by a group from the University of Nebraska Medical Center. The authors 
Wen et al (2014) observed specific and novel variances in each family related to familial 
breast cancer. Moreover, they strongly recommended that adding and analyzing 
phenotypic data might dramatically enhance genetic prediction and the accuracy of 
disease diagnosis [21]. 
 By following the recommendation stated in Wen et al (2014), we have used the 
genomic and phenotypic combination data to predict the SNP effect. To assure that this 
procedure is a novel study, we searched and compared all the studies that were cited in 
Aguilar et al (2010) by using Google Scholar and the Web of Science. As far as we 
know, this work is the first study focusing on human breast cancer that has used this 
innovative methodology. 
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1.2 Data 
 The data in this study was gathered from three families with BRCAx as exome 
sequences, as examined in a study by Wen et al (2014). This data has also been described 
in another study from the University of Nebraska Medical Center by Lynch et al (2013) 
[22]. The use of this data in both studies was approved by the University of Nebraska 
Medical Center and the Institutional Review Boards of Creighton University. All 
members of these families had signed a consent form to participate in cancer research, 
with the understanding that personal information would be kept confidential, as required 
by institutional privacy policies. A detailed discussion of the data can be found in the data 
preparation section of Chapter 3. 
1.3 The Objects of This Study 
 The goal of this study was to estimate the genetic parameters of this disease by 
combining both the phenotypic and genomic information available to us. In addition, this 
study aims to find genomic regions and specific genes with major effects associated with 
familial breast cancer incidences. The general objectives this study were: 
1. Prepare appropriate data for GWAS. This includes mapping to the reference 
genome, removing duplicate reads, calling variants for each individual, and 
merging them with the reference genome. 
2. To estimate variance components and heritability for familial breast cancer 
incidence. 
3. To find genomic regions and specific genes with major effects associated with 
familial breast cancer incidences using both genomic and phenotypic data. 
To achieve these goals, the dissertation is organized as follows: 
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  In Chapter 2, we present GWAS. Chapter 3 deals with the data preparation and 
also defines standard terminologies in genomic studies, such as the structure of DNA, 
gene, SNP, data and families. Additionally, the data preparation steps include mapping, 
removing duplicates, SNPs calling, converting SNPs to integers and quality control for 
genomic data. Chapter 4 describes the methods used, including linear mixed effects 
models, maximum likelihood estimation, numerator relationship matrix, the heritability 
coefficient, genomic relationship matrix, threshold model and the Gibbs sampling 
method. In Chapter 5, multi-trait models will be presented, while Chapter 6 explains the 
analysis using the software FORTRAN90/95 for variance components heritability and for 
prediction of SNP effects and the R software for graphics. The last Chapter is the 
discussion and conclusion. Figure 1.1 shows the version datasets and matrices used in the 
data analysis. 
 
 
 
 
 
Figure 1.1 Flowchart of the data and model matrices. 
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CHAPTER 2 
CANCER AND GENOME-WIDE ASSOCIATION 
2.1 Introduction 
 Cancer is the general name used to refer to a variety of similar diseases, all of 
which involve some cells in the body that are continuously dividing and taking over the 
tissues surrounding the affected area. Cancer can start just about anywhere in the human 
body. In a healthy body, human cells divide to produce replacement cells when needed. 
These new cells replace old damaged ones when they stop working. The development of 
cancer in the body, however, breaks down this otherwise methodical progression. As 
abnormality takes over, the cells that should die and be replaced actually endure, and 
replacement cells continue to form even when they are not required. The extra cells 
multiply endlessly and become tumors. 
 Most common types cancer produce solid tumors or masses of tissue. However, 
blood cancers, such as leukemia, do not typically form tumors. When a tumor is 
cancerous, it is referred to as “malignant”, which means it can attack nearby tissues.  As 
these tumors grow, some cancer cells can even break away from the original mass and 
migrate to other areas in the body through the bloodstream or the lymph system. They 
then start new tumors in locations other than the original site. Benign tumors differ from 
malignant tumors. Though they can also be quite large, they do not take over or attack 
nearby tissues. Benign tumors can be successfully removed and typically there is a big 
chance that will not come back again. However, malignant cancers can be removed but 
can continue to be produced in the body after removal. Benign brain tumors can be life 
threatening but most other benign tumors are not [23]. 
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 Remarkable advancements in cancer study into the past 50 years have provided 
insights into the development of cancer cells. Cancer is now defined as a disease in which 
there are changes or mutations in the cell genome. These changes, or Deoxyribonucleic 
acid (DNA) mutations, produce a protein that upsets the protocol between the cell 
division stage and the dormancy stage, allowing continuous cell division and the 
formation of cancer. At the point when cancer cells relocate to different parts of the body 
where they form new tumors and crowd out normal cells, it is called "metastasis" [25]. 
2.2 Genes Related to Breast Cancer 
 Breast cancer is a main cancer in women. It affects nearly a quarter of a million 
women each year in the United States alone. About 10–15% of breast cancers have 
genetic ties, affecting multiple family members over generations. Recognizing that a 
genetic predisposition increases susceptibility is a big step in unraveling the cause of 
breast cancer for early detection, diagnosis, prognosis, and treatment [26]. 
 Broca was the person to recognize a family with a high prevalence of breast 
cancer in 1866. His wife was inflicted with early onset breast cancer. When Broca trailed 
her family tree, he found four generations with a history of breast [24]. The "Broca" 
report was of many that tied breast cancer to genetic predisposition, passing from one 
generation to the next. He also discovered 16 cases of cancer across five generations in 
one family. Fifteen were female, nine of which had breast cancers [27]. 
 In 1972, Lynch et al. linked breast cancer with a predisposition to colon cancer. 
His findings showed that the members of some families with breast cancer also had a 
comparatively high predilection for cancer of the colon; some showed higher 
predispositions for gastric, ovarian, and endometrial carcinoma, and some demonstrated 
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higher odds for brain tumors, sarcoma, and leukemia. Hall et al (1990) started mapping 
the genes accountable for hereditary breast cancer, which allowed for the identification of 
early lesions that are a signature of the development of breast cancer. He theorized that 
Chromosome 17q21 appeared to be the position of the gene indicating a predisposition to 
breast cancer in families with a history of early-onset diseases. Shortly thereafter, in 
1991, Lenoir et al. demonstrated an association to this same gene position with HBOC 
syndrome. The gene has since become known as "BRCA1". In 1994, Miki and Swensen 
noticed a strong potential for the BRCA1 gene, as it affects the predisposition to breast 
and ovarian cancer. It has also been known for its positional cloning method, which is a 
method to identify genes [29, 32]. 
A study by Wooster et al (1994) provided evidence of another locus to breast 
cancer susceptibility, BRCA2, to a 6-centimorgan interval on chromosome 13q12-13. 
Initial findings suggest that BRCA2 assumes a higher risk of breast cancer but, unlike 
BRCA1, does not impose any elevated risk of ovarian cancer. Mutations in BRCA 1 and 
BRCA 2 are found in most of the families having six or more cases of breast cancer, 
which is aligned with dominant inheritance [34]. However, Shih et al (2002) and Easton 
et al (1999) said that, overall, the identified susceptibility genes are estimated to be 
accountable for less than 25% of familial breast cancer, demonstrating a strong 
possibility that other susceptibility genes are yet to be discovered [36]. Antoniou et al 
(2003) said genetic mutations in BRCA1 and BRCA2 genes can increase the risk of 
breast cancer (60-85%) and ovarian cancer (15-40%) over a lifetime. Researchers have 
attempted to discover an assumed BRCAx gene using linkage analysis to support the 
genetic context for high-risk families. However, the results seem to show that many 
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genes are probably contributors to a predisposition to breast cancer [22, 37]. Others 
hypothesized that the genetic predispositions in many BRCAx family breast cancer cases 
may be specific variations [21]. Correspondingly, several studies showed that the risk of 
breast cancer could be increased with mutations in the following genes: P53, PTEN, 
CHEK2, ATM, PLAB2, FGFR2 and TNRC9; other genes are still being vetted [21]. 
Current evidence suggest that three types of genetic predisposition exist for 
familial breast cancer: (a) high-risk genes with rare mutations, but high penetrance 
causing high risk of breast cancer, e.g., BRCA1 and BRCA2; (b) intermediate-risk genes 
with rare mutations causing intermediate risk of breast cancer, e.g., CHEK2, ATM, 
BRIP1, and PALB2; and (c) common modest risk genetic variants, such as the SNPs in or 
close to FGFR2, TNRC9, MAP3K1, and LSP1[22].  
2.3 Genome-Wide Association Analysis for Breast Cancer  
 Identifying and understanding genetic risk factors for complex diseases is the 
main goal of human genetics. GWAS is one of several beneficial technologies used to 
study designs and examine the results of analytical tools in order to identify genetic risk 
factors. GWAS examines the whole genome in different individuals to see if there are 
any genetic regions related to a specific trait. Determining a genetic factor will help in 
tracking the disease and in discovering cancer in early stages. In addition, this can lead 
the way to additional possible treatments. This information can be used in fine mapping 
genes [38]. 
 The first scientific report using genome-wide screening was in 2005 [39]. The 
researchers examined patients with age-related macular degeneration and found two 
SNPs with significantly different allele frequencies compared to healthy control subjects. 
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Many similar studies that have been reported successfully using the genome-wide 
association analysis to determine genetic variations that might contribute to a risk of type 
2 diabetes, Parkinson's disease, heart disorders, obesity, Crohn's disease and prostate 
cancer, as well as genetic variations that influence responses to antidepressant 
medications [39, 40]. 
 In recent years, several genetic SNPs related to breast cancer risk have also been 
identified via GWAS [22]. Haiman et al (2011) combined GWAS data from women of 
African ancestry (1,004 ER-negative cases from 2,745 controls) and European ancestry 
(1,718 ER-negative cases out of 3,670 controls), with replication testing conducted in an 
additional 2,292 ER-negative cases and 16,901 controls of European ancestry. A common 
risk variant for ER-negative breast cancer at the TERT-CLPTM1L locus on chromosome 
5p15 (rs10069690) was discovered. The variant was also implicitly linked to triple-
negative (ER-negative, progesterone receptor (PR)-negative and human epidermal 
growth factor-2 (HER2)-negative) breast cancer, particularly in younger women (<50 
years of age) [41]. 
 Another study in GWAS cited single-nucleotide polymorphisms at 1p11.2 and 
14q24.1 as loci for breast cancer susceptibility. The early GWAS leaned in the direction 
of strong effects for both loci for ER-positive tumors. Using data from the Breast Cancer 
Association Consortium (BCAC), Figueroa et al (2011) sought to determine whether 
risks differ by ER, progesterone receptor (PR), human epidermal growth factor receptor 2 
(HER2), grade, node status, tumor size, and ductal or lobular morphology. The data was 
derived from 46,036 invasive breast cancer cases and 46,930 controls from 39 studies. 
Analyses by tumor characteristics focused on subjects identifying as white women of 
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European ancestry and were based on 25,458 cases, of which 87% had ER data. The SNP 
at 1p11.2 revealed pointedly stronger associations with ER-positive tumors [42]. 
 In the Triple Negative Breast Cancer Consortium (TNBCC) Stevens et al (2011) 
explored 22 common breast cancer susceptibility SNPs in 2,980 Caucasian women with 
triple negative breast cancer and 4,978 healthy controls. Six SNPs significantly related 
with risk of triple negative breast cancer were also identified, including: rs2046210 
(ESR1), rs12662670 (ESR1), rs3803662 (TOX3), rs999737 (RAD51L1), rs8170 
(19p13.11) and rs8100241 (19p13.11) [43].  
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CHAPTER 3 
DATA PREPARATION 
3.1 Introduction 
 In GWAS studies, researchers use complicated datasets, with the data needed for 
the final statistical modeling usually prepared in multiple steps. In this chapter, we tried 
to describe the various data preparation steps we used in our study. These steps include 
mapping, remove duplicates, SNPs calling, converting SNPs to integers and quality 
control for genomic data. We also give a short overview to the standard terminology used 
in genomic studies.   
3.2 The Structure and Function of DNA 
In the 1940s, biologists struggled to understand how DNA could be the key to our 
genetic make-up, due to the assumed simplicity of its configuration. There was awareness 
that DNA was comprised of four similar types of subunits laced together on a long 
polymer, and that each of the four subunits resembled one another chemically. In the 
early 1950s, DNA was studied by way of a procedure known as x-ray diffraction 
analysis, that distinguished the three-dimensional atomic structure of molecules. The 
preliminary findings of the x-ray diffraction exposed that the configuration of DNA was 
formed by two polymer strands spiraled into a helix (Figure 3.1 [147]). The detection of 
the two-stranded structure of DNA was revolutionary, becoming one of the most 
prominent pieces of evidence that led to the Watson-Crick Model for DNA structure. It 
was only once this model was proposed in 1953 that DNA's capacity for replication and 
material encoding become evident [44]. 
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DNA is the hereditary material in humans and almost all other living organisms; 
in fact, the same DNA is present in almost every cell in a human body. DNA is most 
generally located in the cell nucleus. This type of DNA is called nuclear DNA. Small 
amounts of DNA are also found in mitochondria; this type of DNA called mtDNA. 
 
 
 
 
 
 
 
 
 
 The information in DNA is stored as a code made up of four chemical bases: The 
The four nucleobases that comprise the chemistry of DNA are Adenine (A), Guanine (G), 
Cytosine (C), and Thymine (T). More than 99 percent of the roughly 3 billion bases of 
which human DNA is comprised are identical in all people. The bases line up in different 
arrangements in order to regulate the information needed to create and sustain an 
organism, much like individual letters of the alphabet can combine in different orders to 
form a variety of words and phrases [45]. 
 Base pairs occur when two DNA bases attach to each other, such as A joins with 
T and C joins with G. Additionally, every base pair adds a sugar and a phosphate 
molecule. So the nucleotide is a combination of sugar and phosphate. Nucleotides join 
together to create the famous double helix building of DNA. The double helix is formed 
Figure 3.1 The two strands of DNA. 
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in a ladder-like spiral, with the base pairs connecting horizontally, much like ladder 
rungs, while the sugar and phosphate molecules create long vertical strands. Possibly the 
most important characteristic of DNA is its ability to produce exact duplicates of itself. 
 The critical process of cell division relies on the exact replication of the DNA to 
create a new cell so each new cell is a perfect copy of the original. Each double-stranded 
DNA molecule has the ability to reproduce its base pairs in sequence [44]. 
3.3 What is a Gene 
 DNA molecules (comprised of base pairs) make up the standard material and 
practical element of heredity, known as a gene. Genes, in turn, contain the information 
necessary to create molecules called proteins, which are essential for maintaining the 
body’s muscles, tissues, and organs (Figure 3.2 [148]). Human genes, for example, show 
a great variety in size, ranging from just a few hundred base pairs to more than 2 million. 
Research from the Human Genome Project indicates humans may have up to 25,000 
genes. Over 99 percent of the genes are identical in every human. Each parent passes on a 
complete set of its genes; as a result, each person has two copies of every gene. In fewer 
than 1 percent of genes, the gene pairs have different patterns in their DNA bases; those 
gene pairs are known as alleles. Alleles are responsible for each person’s individual 
corporeal differences [44]. 
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Figure 3.2 A part of a DNA molecule coding. 
3.4 Single Nucleotide Polymorphisms 
 As discussed above, DNA patterns are made up of chains of nucleotide bases (A, 
C, G and T). A difference at a specific location in a DNA pattern of an individual is 
known as a single nucleotide polymorphism, or SNP (Figure 3.3 [149]). This deviation 
can be classified as an SNP only if it is present in less than 1 percent of a given 
population. A gene can be considered to have two alleles if an SNP occurs in that gene. 
An SNP inside a gene can alter the pattern of the amino acids. SNPs do not only occur 
within genes, but can also be found in DNA molecules that do not carry instructions for 
producing proteins, which named noncoding region.  
Figure 3.3 Single nucleotide polymorphism in six persons. 
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 Although a particular SNP may not create a disorder, some SNPs are related to 
the occurance of certain diseases. These associations enable scientists to search for SNPs 
in order to assess an individual's genetic predisposition to developing a disease. 
Additionaly, if certain SNPs are understood to be correlated with a trait, then scientists 
may inspect stretches of DNA near these SNPs in an effort to detect the gene or genes 
responsible for that trait. Researchers are hopeful that awareness of an individual’s SNP 
genotype will afford a basis for evaluating susceptibility to diseases and the ideal choice 
of therapies [46]. A key challenge in understanding these potentials is comprehending 
how and when the variants may cause a disease. 
3.5 Data 
 This study used exome sequencing data. The data was previously analyzed in the 
study by Wen et al (2014) to test genetic predispositions; in their study, only genomic 
data was used. They matched all variants that were identified in the databases, while all 
known variants were removed. The study includes data from three families with BRCAx 
familial breast cancer (refer to Figure 3.5-3.7 and Appendix A); the families included 
seventeen members with cancer, and five members without. In the first family, seven 
members had cancer and one member was healthy, while in the second family, five 
members had cancer and three did not. The third family included five members who had 
cancer and one who remained unaffected. Data in this work were collected as blood 
samples from family that have members affected by cancer, as well as those who were 
not affected. The thorough genetic testing of individuals in each family displayed no 
mutation in BRCA1 or BRCA2. Family members over two generations were chosen for 
exome sequencing based on the pedigree’s hereditary pattern of breast cancer, as well as 
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the accessibility of DNA samples. Exome sequences were collected with a HiSeq™ 2000 
sequencer (Illumina, San Diego, CA) with a paired-end (2 × 100).  
3.6 Paired-End Reads 
       Paired-end reads permit users to sequence both ends of a fragment, which generates 
superior sequence data that can be easily aligned (Figure 3.4 [150]). In addition to gene 
fusions and unusual transcripts, paired-end sequencing enables detection of genomic 
changes and elements of a repetitive sequence.  
        Subsequently, paired-end reads are more able to line up to a reference, and the value 
of the total data set is much improved. All Illumina next-generation sequencing (NGS) 
structures are capable of paired-end sequencing. 
 
Figure 3.4 Paired-end sequencing. 
 
 
 
 
 
 
18 
 
 
 
Figure 3.5 The pedigree information of family 1. 
 
Figure 3.6 The pedigree information of family 2. 
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Figure 3.7 The pedigree information of family 3. 
3.7 Pipelines 
 Pipelines are series of computational or data manipulation steps that result with 
specific data called “variants”, which are analyzable in the next-generation sequencing 
studies, all these steps are shown in (Figure 3.8). Before we go to detail let us define 
some terms; Reads: are sequences obtained of DNA, where each nucleotide sequences 
called read. Usually each read has 100 base pair; Bowtie 2: is a tool to align sequencing 
reads to reference sequences; Picard: is a tool to operate specific format such as SAM, 
bam and VCF file; SAMtools: is a tool that use alignments in BAM format; BCFtools: 
this tool to call variant as VCF and BCF format. 
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Figure 3.8 Flowchart of data preparing steps. 
3.7.1 Mapping with Bowtie 2 
 The primary measure in several relative genomic pipelines is aligning sequencing 
reads to a reference genome, such as variant calling, isoform quantitation, and differential 
gene expression. In many instances, the alignment step is the longest, since for each read, 
the aligner has to resolve the difficult computational problem of ascertaining the read’s 
most likely point of origination regarding a reference genome. Most aligners use a 
genome index to quickly narrow down the list of potential alignment locales. The full-
text minute index is a fast and memory-efficient index that is being utilized by aligners. 
Index-assisted aligners function by looking for all the potential ways to mutate the read 
string into a string. This also happens to the reference point, which is of course, an 
alignment rule, and thereby limits the number of changes. Even though this search space 
is vast, several areas can be bypassed (pruned) without loss of precision. Pruning 
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approaches such as double indexing and bidirectional Burrows-Wheeler Transform 
(BWT) allow a rapid and thorough alignment of short reads [47]. 
 For each read, Bowtie 2 is conducted in four steps (Supplementary Note and 
Supplementary). Step 1 of Bowtie 2 involves extracting ‘seed’ substrings from the read 
and its reverse complement. In step 2, the removed substrings are aligned to the reference 
without gaps, using the full-text minute index. For step 3, the seed alignments are ranked, 
and their locations in the reference genome are determined from the index. Finally, in 
step 4, the seeds are stretched into full alignments by executing SIMD-accelerated 
dynamic programming. 
 Langmead and Salzberg (2012) likened Bowtie 2 to four other full-text minute 
index–based read aligners. Included in their comparison was Burrows-Wheeler Aligner 
(BWA), BWA’s Smith-Waterman Alignment (BWA-SW) and Short Oligonucleotide 
Alignment Program 2 (SOAP2), and Bowtie. They attained 100-by-100 nucleotide (nt) 
paired-end HiSeq (2000) reads from a human resequencing study and took out an 
arbitrary subsection of 2 million pairs. They found that the Bowtie 2 default mode was 
quicker than the other BWA modes and was faster by more than 2.5 times over the BWA 
default mode.  All of the Bowtie 2 modes aligned a larger number of reads than either 
BWA or SOAP2. In summary, they found in all cases, Bowtie 2 and BWA found more 
accurate alignments than SOAP2 and Bowtie. Bowtie 2 also presented more accurate and 
fewer inaccurate alignments for the unpaired reads than BWA presented over an area of 
charting quality limits. For paired-end reads, the disparity was reduced. 
 We have mapped data in this study while considering the human genome (hg 19) 
as a reference sequence using Bowtie 2 with default parameters. The rate of overall 
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alignment for each subject was around 92% see Appendix B for statistics from Bowtie 2. 
The output was formatted as a SAM file, then we converted it to the BAM format using 
SAMtools utility [47]. 
3.7.2 Getting Rid of Duplicates using Picard 
 It has been observed that some reads pile up with the same beginning and ending 
coordinates. These may be a product of PCR duplicates. The occurrence of these 
replicates injected by PCR expansion is a key problem in paired short reads from next 
generation sequencing. These replicates should be removed from BAM files as they may 
have a critical and adverse effect on research applications. Even more crucial is the fact 
that the precision of paired reads alignment could be compromised by genomic variations 
that are broadly dispersed among individuals, such as copy number variations, extensive 
structural variations, minor insertion or deletion (indels) variations, and SNPs. Duplicates 
for this study were removed using Picard Mark Duplicates, which is the favored method 
for this purpose [48]. 
3.7.3 Recalibration and Interrelation 
 The Genome Analysis ToolKit (GATK) is a software capable of incorporating the 
evidence for variants from several samples with joint genotyping. It enables the use of 
validated SNPs and indels to augment the accuracy of variant calling [49]. However, 
many research communities lack the large, validated collections of SNPs and indels 
needed to test using GATK’s Best Practices procedures due to the investment required to 
obtain and curate such collections [50]. To work around the necessity for large-scale 
variant validation studies, McCormick et al (2015) created the Recalibration and 
Interrelation of genomic sequence data with the GATK workflow. This development 
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integrated data from multiple genomic sources and identified reliable sets of variants. A 
variety of factors exist that could cause erroneous results: inadequate or incorrect 
reference assemblies, mistaken realignment of reads to the reference genome (mainly in 
lower complexity regions and around indels), inexact base quality scores, and suboptimal 
variant filtration parameters [49, 51]. Additionally, the recalibration tool tries to improve 
variation quality with the machine cycle and sequence context, and by doing so, provides 
not only more precise quality scores but also more broadly dispersed ones [52]. 
 We recalibrated the base quality scores of the sequencing by synthesizing reads 
into an aligned BAM file. Once completed, the quality scores in the QUAL field of each 
read in the output BAM were more precise, in that the reported quality score was closer 
to its actual probability of mismatching the reference genome. 
3.7.4 SNPs Calling via SAMtools and BCFtools 
 One of the standard tasks for NGS studies is the detection of SNPs and indels in 
an individual sample. SAMtools enables users to call both types of variants concurrently 
using the mpileup output. In this study, variants have been called as BCF format using a 
specific parameter (--skip-indels).  At each position, the SAMtools searches for variants 
that qualify under user-defined minimum conditions for sequence reporting. The 
conditions included the quantity of supporting reads. After using BCFtools to call SNP’s 
variants with the parameters -c -v (call genotypes and output variant sites only), files are 
output in the Variant Call Format (VCF) format [53]. See Appendix C for output from 
SAMtools to call SNP.   
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3.7.5 Converting SNPs to Integers 
 VCF is a text file format used for the storage of marker and genotype data. The 
following example (Table  [54]) explains how VCF encodes data for SNPs. 
Table 3.1 Variant Call Format. 
 
 
 
 Each column included after first nine has genomic information called genotype.  
For sample data, GT alleles are numeric; the reference REF is 0, the first ALT is 1, and 
so on. As an example, the genotypes for SAMP001 (The tenth column in Table ) are a 
homozygous reference first, followed by a heterozygous and third, a missing record. 
 Missing observations with levels of SNP data in some genetic analysis can offer 
good estimations of genetic parameters; however, little is known about the influence of a 
missing level that is higher than 90%.  Traditionally, if the missing level is 15% or below, 
it is known to eliminate genetic markers with incomplete observations [55, 56]. Missing 
genotypes data will not include the calculations, so but we coded them 5 following 
VanRaden (2008) method [57].  
 Our data included 22 subjects (columns) with approximately 16 million SNPs 
(rows), so the rows with more than two missing SNPs were removed. This resulted in 
more than 10% of the missing levels being eliminated to obtain estimations of genetic 
parameters reliability. Refer to the following table (Table 3.2) which shows some of the 
SNP data used. This sample represents family 1, which has eight individuals x1- x8. The 
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numbers 0 and 2 represent recessive and dominant homozygous genes, with 1 being 
heterozygous and 5 denoting missing alleles. We will use this data set in matrix 𝐌 which 
is a genomic relationships matrix (𝑮). Refer to Section 4.7 for additional details.  
Table 3.2 SNPs coded data. 
CHROM POS x1 x2 x3 x4 x5 x6 x7 x8 
1 808922 2 2 2 0 0 0 2 2 
1 880238 0 0 0 0 0 0 0 0 
1 883625 0 2 0 0 0 5 0 5 
1 887560 2 0 1 1 1 1 0 1 
1 887801 0 0 0 0 0 0 0 0 
1 888639 2 0 0 0 2 0 0 2 
1 888659 0 0 2 0 0 2 0 0 
1 889158 0 0 0 0 0 0 0 0 
1 889159 2 0 2 0 2 0 0 0 
. . . . . . . . . . 
. . . . . . . . . . 
. . . . . . . . . . 
. . . . . . . . . . 
. . . . . . . . . . 
22 43520263 0 2 0 0 2 0 0 1 
22 43528793 2 2 2 0 2 0 0 1 
3.8 Quality Control for Genomic Data 
 Quality control (QC) of genotypes is vital to avoid false results in genome-wide 
association studies. Maintaining long-term data integrity is also of the utmost importance, 
especially in situations with ongoing genotyping. Some SNP data was problematic to 
score because of an irregular genotype clustering pattern. Procedures were performed to 
improve SNP data (25394 SNP's), including the following steps: 
1) 22 markers were removed from the mitochondrial chromosome. 390 were 
removed from chromosome X because some noteworthy biological insights could be 
garnered by the exclusion of the X chromosome in the GWAS analysis. 
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2) SNPs with a low Minor Allele Frequency (MAF) were removed. As a rule, an 
MAF threshold of 1-2% is used, but studies with smaller sample sizes might require a 
higher threshold [58]. 25% was the threshold used to determine the MAF for calling 
SNPs. 
3) Because the precision of genotyping is extremely reliant on the quality of the 
genotypes, repeated genotyping of the same samples could be misread as originating 
from different individuals when call rates drop under 90% [59]. Therefore, all SNPs with 
a call rate < 90% were ignored. 
4)  Most GWAS studies choose to eliminate markers that display significant 
deviation from Hardy-Weinberg Equilibrium (HWE) because it can indicate a genotyping 
or genotype calling error. On the other hand, variances from HWE might also show 
selection; a sample can display deviations from HWE at loci related to a disease; it would 
clearly be counter-productive to exclude these loci from a deeper inquiry. In practice, 
many SNPs with an HWE p-value less than 0.001 will be extracted. However, robustly 
genotyped SNPs, even if under this threshold, will remain under study. Upon checking, 
the departure of heterozygous from Hardy-Weinberg Equilibrium using default value 
0.15 resulted in 17857 SNPs that were ready to use [58, 60]. 
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CHAPTER 4 
METHODOLOGY 
4.1 Introduction 
 This chapter focuses on the methodologies that are used in the estimation of 
heritability coefficient and prediction of SNP’s effects. Because the response variable in 
this study is binary (affected or normal), threshold model is employed. The idea of this 
technique is based on linear mixed effects models (LME) which are suitable methods in 
case of continuous response variables. In order to estimate the variance components, we 
utilize Gibbs Sampling. 
4.2 Literature Review on GWAS  
 For modeling population relationships in Genome-Wide Association studies, 
LME models have been recommended [61]. LME models expand on the work initially 
described in the literature dealing with animal breeding. Later it was developed in the 
human genetics literature, in which, an interesting genetic effect (e.g., the number of 
copies of a specific allele at a specific test SNP) as a random effect, with an added fixed 
effect is incorporated to model the genetic relationship between individuals [62]. In the 
first few years of GWAS, linear mixed effects models were not used much due to 
computational issues [63]. In more recent years, a wide array of LME methods/software 
packages have surfaced [62]. 
 In statistical analysis, needless to mention, it is critical to know the nature of our 
dependent variable and model it using appropriate methods. Tong et al (1976, 1977) and 
Berger and Freeman (1978) translated the categorical response into a quantitative 
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response by assigning m ordered numerical values or "scores" to the m categories. They 
then proceeded as though this discrete quantitative response followed a linear mixed 
effects models. Unfortunately, the assumptions implicit in many common linear mixed 
effects models, including those of homogeneity of variances, may be much less 
reasonable when the model is applied to a discrete response than when it is applied to a 
continuous response [67]. 
 Linear mixed effects models have commonly been used in the study of continuous 
traits (e.g., see Anderson et al (2010)). They are grounded in the supposition of normality 
and are easily implemented using the software that is available to the public. In the case 
of  longitudinal data we refer to Molenberghs and Verbeke (2000) and Fitzmaurice et al 
(2011). However, results from a linear mixed effects models may be unreliable under 
certain circumstances, such as, if the assumed Gaussian distribution of the response 
variable is not met, for instance, due to the occurrence of outliers or skewness. 
Alternatives include data transformation or a more adaptable modeling tactic [71, 72]. 
Ordered categorical traits are usually studied applying the threshold liability model, 
which was first used by Wright (1934) in the analysis of the quantity of digits in guinea 
pigs (normally have four front feet). It was also used by Bliss (1935) in toxicology trials. 
In the threshold model, it is hypothesized that there is an underlying or latent variable 
(liability) that has a continuous distribution [73]. A response in a specified category is 
noted if the value of liability lies between the thresholds, determining the suitable 
category [74-76].  
 When variability originates from two sources, linear mixed effects models and 
threshold model with two variance components are commonly used. In genetic studies, 
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variation in observations can be credited to biological and environmental influences. The 
heritability coefficient is an essential quantity that gauges the percentage of overall 
variability owing to biological influences [14]. Recently, Bayesian methods have been 
developed for variance components estimation [77-81]. As Broemeling (1985) had 
observed, each of these reviews discovered analytically intractable joint posterior 
distributions of variance components. Additional marginalization regarding dispersion 
parameters appears to be problematic or impossible by means of analytic. New 
developments in computing have fostered the use of numerical methods in Bayesian 
inference. For instance, following studies by Hammersley and Handscomb (1964), Kloek 
and Van Dijk (1978), and Rubinstein and Kroese (1981) have been used these numerical 
methods in econometric and Bauwens (1984,1988) in binary responses models [90]. 
 Markov Chain Monte Carlo (MCMC) methods have granted computation of 
multidimensional integrals so analytic approximations can thus be avoided. Usage of the 
Gibbs sampler to analyze ordered categorical traits has been described by Zeger and 
Karim (1991) and Albert and Chib (1993). It was used by McCulloch et al (1994) and 
Sorensen (1995) to estimate variance components for binary data [75]. 
4.3 Linear Mixed Effects Models 
 Linear mixed effects models are beneficial in a variety of physical, biological, and 
social scientific applications with variability coming from multiple sources [94, 95]. 
Linear mixed effects models are extensions of standard linear models (e.g., linear 
regression and ANOVA). Linear mixed effects models contain fixed and random effects 
hence called linear mixed effects. 
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A linear mixed effects model is given by 
𝒀 = 𝑿𝜷 + 𝒁𝒅 + 𝜺                                                       (4.1) 
where 𝒀 is a vector of observations with dimension 𝑛 × 1, 𝜷 is a vector of fixed effects 
with dimension p×1, 𝒅 is a vector of random effects with dimension 𝑞 ×  1. 𝑿 and 𝒁 are 
design matrices for the fixed and random effects with dimensions 𝑛 × 𝑝 and 𝑛 × 𝑞, 
respectively. The vector of random effects is distributed as normal with mean 0 and 
variance-covariance matrix 𝛀, 𝒅~𝑁(𝟎,𝛀). And 𝜺 is a vector of normal random errors 
with means 0 and variance-covariance matrix 𝑹, 𝜺~𝑁(𝟎,𝐑). The vectors of random 
effects 𝒅 and error term 𝜺 are assumed to be independent. Therefore, 
𝑉𝑎𝑟 [
𝒅
𝜺
] = [
𝛀 𝟎
𝟎 𝑹
] 
The expected value of 𝒀 is 
𝐸(𝒀) = 𝐸(𝑿𝜷 + 𝒁𝒅 + 𝜺) = 𝑿𝜷     ;       since 𝐸(𝒅) =  𝐸(𝜺) = 𝟎. 
The variance-covariance matrix of 𝐘 is 
 𝐕 = 𝑉𝑎𝑟(𝒀) = 𝑉𝑎𝑟(𝑿𝜷 + 𝒁𝒅 + 𝜺)   
= 𝑉𝑎𝑟(𝒁𝒅 + 𝜺) =  𝐙𝛀𝒁′  +  𝐑 ; since 𝒅 and 𝜺 are independent. 
The distribution of 𝐘 can be defined in two ways: 
i. The marginal distribution of 𝒀 not knowing the random effects 𝒅 is normal with 
mean 𝑿𝜷 and variance-covariance matrix 𝐕. In other words 
𝒀~𝑁(𝑿𝜷, 𝑽). Hence, the pdf of 𝒀 is: 
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𝑓(𝒚) =
1
(2𝜋)𝑛/2|𝑽|1/2
 exp [
−1
2
 (𝒚 − 𝑿𝜷)′𝑽−𝟏(𝒚 − 𝑿𝜷)]. 
 One difficulty in linear mixed effects models is that 𝐕 =  𝐙𝛀𝒁′ +  𝐑 is large and 
often non-diagonal. Therefore, 𝐕−1 is difficult or impossible to compute by common 
methods [96]. In general, the inverse of 𝐕 is given by: 
𝐕−1 = 𝑹−1 − 𝑹−1𝒁( 𝒁′𝑹−1𝐙 + 𝛀−1)𝒁′𝑹−1 
This is true since for three nonsingular matrices A, B and C 
(𝑨 + 𝑪𝑩𝑪′)−1 = 𝑨−1 + 𝑨−1𝑪(𝑩−1 + 𝑪′𝑨−1𝑪)𝑪′𝑨−1 
and                              (𝑨𝑩𝑪)−1 = 𝑪−1𝑩−1𝑨−1 
ii. The conditional distribution of the dependent variable 𝒀 given the random effects 
𝒅 is normal with mean 𝑿𝜷 + 𝒁𝒅 and variance-covariance matrix 𝑹. In other 
words, 𝒀|𝒅~𝑁(𝑿𝜷 + 𝒁𝒅,𝑹). Therefore, the pdf is given by 
𝑔(𝒚|𝒅) =
1
(2𝜋)𝑛/2|𝑹|1/2
exp [
−1
2
 (𝒚 − 𝑿𝜷 − 𝒁𝒅)′𝑹−𝟏(𝒚 − 𝑿𝜷 − 𝒁𝒅)]. 
4.4 Maximum Likelihood Estimation of Parameters 
4.4.1 Case I: 𝛀 and 𝑹 are known 
 If matrices 𝛀 and 𝑹 are known, then ?̂? is the best linear unbiased estimation 
(BLUE) of 𝜷 and ?̂? is the best linear unbiased prediction (BLUP) of 𝒅 [97-100]. The 
estimates of 𝜷 and 𝒅 can be found by maximizing the likelihood in 𝜷 and 𝒅 in the joint 
density function of 𝒀 and 𝒅 as follows. 
𝑓(𝒚, 𝒅 ) = 𝑔(𝒚|𝒅)ℎ(𝒅), 
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where ℎ(𝒅) is the pdf of 𝒅. The likelihood function is 
𝐿(𝜷, 𝒅) = 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 × exp [
−1
2
 (𝒚 − 𝑿𝜷 − 𝒁𝒅)′𝑹−𝟏(𝒚 − 𝑿𝜷 − 𝒁𝒅) −
1
2
𝒅′𝛀−𝟏𝒅].  
The log-likelihood function is 
𝑙(𝜷, 𝒅) = log(𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡) −
1
2
 [(𝒚 − 𝑿𝜷 − 𝒁𝒅)′𝑹−𝟏(𝒚 − 𝑿𝜷 − 𝒁𝒅) + 𝒅′𝛀−𝟏𝒅]. 
For 𝜷:  
𝜕𝑙(𝜷, 𝒅)
𝜕𝜷
= −
1
2
 [(𝒚 − 𝑿𝜷 − 𝒁𝒅)′𝑹−𝟏(−2𝑿)] 
= [(𝒚 − 𝑿𝜷 − 𝒁𝒅)′𝑹−𝟏(𝑿)] 
By equating this partial derivative to zero and taking transpose, we get: 
𝑿′𝑹−𝟏𝑿𝜷 + 𝑿′𝑹−𝟏𝒁𝒅 = 𝑿′𝑹−𝟏𝒀                                            (4.2) 
For 𝒅: 
𝜕𝑙(𝜷, 𝒅)
𝜕𝒅
=  −
1
2𝜎2
 [(𝒚 − 𝑿𝜷 − 𝒁𝒅)′𝑹−𝟏(−2𝒁) − 2𝒅′𝛀−𝟏] 
−
1
2𝜎2
 [(𝒚 − 𝑿𝜷 − 𝒁𝒅)′𝑹−𝟏(−2𝒁) − 2𝒅′𝛀−𝟏] 
Equating this partial derivative to zero and taking transpose we get: 
𝒁′𝑹−𝟏𝑿 𝜷 + (𝒁′𝑹−𝟏𝒁 + 𝛀−𝟏)𝒅 = 𝒁′𝑹−𝟏𝒚                               (4.3) 
From Equations (4.2) and (4.3), the mixed model equations in matrix notation will be: 
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[𝑿
′𝑹−1𝑿 𝑿′𝑹−1𝒁
𝒁′𝑹−1𝑿 𝒁′𝑹−1𝒁 + 𝛀−1
] [
?̂?
?̂?
] = [
𝑿′𝑹−1𝒚
𝒁′𝑹−1𝒚
]                                   (4.4) 
For further technical details, we refer to [101-103]. 
From Equation (4.3) we have 
(𝒁′𝑹−1𝒁 + 𝛀−1)?̂? =  𝒁′𝑹−1(𝒀 − 𝑿?̂? ) 
⇔          ?̂? =  (𝒁′𝑹−1𝒁 + 𝛀−1)−1 𝒁′𝑹−1(𝒀 − 𝑿?̂? )                                 (4.5) 
and from Equation (4.2) we have 
𝑿′𝑹−1𝑿 ?̂? + 𝑿′𝑹−𝟏𝒁 ?̂? =  𝑿′𝑹−1𝒚. 
Substituting the solution for ?̂? into this equation gives: 
𝑿′𝑹−1𝑿 ?̂? + 𝑿′𝑹−1𝒁 [(𝒁′𝑹−1𝒁 + 𝛀−1)−1 𝒁′𝑹−1(𝒚 − 𝑿?̂? )] =  𝑿′𝑹−1𝒚. 
Let 𝐔 = (𝒁′𝑹−1𝒁 + 𝛀−1)−1, then we have 
                            𝑿′𝑹−1𝑿 ?̂? + 𝑿′𝑹−1𝒁 𝑼 𝒁′𝑹−1(𝒀 − 𝑿?̂? ) =  𝑿′𝑹−1𝒀 
⇔         𝑿′𝑹−1𝑿 ?̂? − 𝑿′𝑹−1𝒁 𝑼 𝒁′𝑹−1𝑿?̂? = 𝑿′𝑹−1𝒀 − 𝑿′𝑹−1𝒁 𝑼 𝒁′𝑹−1𝒀  
⇔                   𝑿′(𝑹−1 − 𝑹−1𝒁 𝑼 𝒁′𝑹−1)𝑿?̂? = 𝑿′(𝑹−1 − 𝑹−1𝒁 𝑼 𝒁′𝑹−1)𝒀  
⇔       𝑿′𝑽−1𝑿 ?̂? =  𝑿′𝑽−1𝒀, 
where  𝑽−1 = 𝑹−1 − 𝑹−1𝒁𝑼𝒁′𝑹−1 
⇔            ?̂? = (𝑿′𝑽−1𝑿) −1 𝑿′𝑽−1𝒀.                                                 (4.6) 
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Hence ?̂? is called the generalized least-square estimate of 𝜷. By plugging this estimator 
into Equation (4.5), we obtain estimate for the vector of random effects 𝒅. 
 In case of general linear models with homoscedastic variance and independent 
residuals, note that 𝐕 = 𝜎𝜀
2𝑰𝑛. Therefore, the least square estimator of 𝜷 will be 
 ?̂? =  (𝑿′𝑿)−1𝑿′𝒀. If the matrix 𝑿′𝑿 is singular, we use a generalized inverse (e.g., see 
Penrose (1955)) [103, 105-107]. 
If the matrix in Equation (4.4) is singular, then the solution for  ?̂? and ?̂? will be based on 
generalized inverse [100] 
[
?̂?
?̂?
] = [𝑿
′𝑹−1𝑿 𝑿′𝑹−1𝒁
𝒁′𝑹−1𝑿 𝒁′𝑹−1𝒁 + 𝛀−1
]
−
[
𝑿′𝑹−1𝒚
𝒁′𝑹−1𝒚
] 
where 𝐌−1 denote the generalized inverse of a matrix 𝐌. 
4.4.2 Case II: 𝜴 and 𝑹 are unknown 
 The matrices 𝑿 and 𝒁 in model (4.1) are known, but the elements of the matrices  
𝜴 and 𝑹 maybe functions of an unobserved parameter vector  𝜽 = (𝜽1, … , 𝜽𝑚)
′ . In 
ordinary mixed effects and random ANOVA models, there is some number c of random 
factors, with the ith factor having 𝑞𝑖 levels. These levels are uncorrelated with each other. 
Associated with the ith random factor is a parameter 𝜎𝑖
2 which represent the common 
variance of its levels. Also, the residual effects have common variance 𝜎𝑐+1
2 . The 
variances 𝜎1
2, … , 𝜎𝑐+1
2  are called variance components. Let 𝑚 = 𝑐 + 1 denote the number 
of variance components then, 
𝜃𝑖 = 𝜎𝑖
2  , (𝑖 = 1,2, … ,𝑚),     𝑹 = 𝜃𝑚𝐈 ,     𝜴 = diag[𝜃1𝐈, … , 𝜃𝑚−1𝐈], 
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𝐕 = 𝜃𝑚𝑰 + ∑ 𝜃𝑖𝒁𝑖𝒁𝑖
′
𝑚−1
𝑖=1
 
where 𝒁𝑖 is a 𝑛 × 𝑞𝑖matrix defined by the partitioning 𝒁 = (𝒁1, … , 𝒁𝑚−1). 
The ANOVA models are sometimes parameterized in terms of 𝛾𝑐+1 = 𝜎𝑐+1
2  and 𝛾𝑖 =
𝜎𝑖
2
𝜎𝑐+1
2  
(𝑖 = 1,… , 𝑐) rather than in terms 𝜎1
2, … , 𝜎𝑐+1
2 . If we had taken 𝛾𝑖 = 𝜃𝑖   , (𝑖 = 1,2, … ,𝑚), 
instead of taking 𝜽, we would have had  
𝜴 = 𝜃𝑚diag[𝜃1𝐈, … , 𝜃𝑚−1𝐈], 
and  
𝐕 = 𝜃𝑚 (𝑰 + ∑ 𝜃𝑖𝒁𝑖𝒁𝑖
′
𝑚−1
𝑖=1
). 
 We will consider both maximum likelihood [28] and restricted maximum 
likelihood (REML) estimators for the variance components. We maximize the full log-
likelihood function 𝑙𝐹 in , 𝜎𝑐+1
2 , and 𝜽: 
𝑙𝐹(𝜷, 𝜎𝑐+1
2 , 𝜽|𝒚) = −
1
2
 log|𝐕| −
1
2
 (𝒚 − 𝑿𝜷)′𝐕−𝟏(𝒚 − 𝑿𝜷). 
 A criticism of the ML estimators for the variance component is that they are 
biased downward because they do not consider the loss of degrees of freedom from the 
estimation of 𝜷. The ML estimator for the single “variance component” 𝜃1 has 
expectation (𝑛 − 𝑝∗)/𝑛, that it is biased downward by an amount 𝜃1𝑝
∗/𝑛, which can be 
significant if the degree of freedom 𝑛 − 𝑝∗ is sufficiently small. Here 𝑝∗ is the rank of the 
design matrix 𝑿. 
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 The REML method corrects for this by defining estimators of the variance 
components as the maximizers of the log-likelihood based on linearly independent error 
contrasts, where 𝑛 is the total number of observations from all individuals. This log-
likelihood 𝑙𝑅 that is derived by Harville (1974) is given as, 
𝑙𝑅(?̂?(𝜽), 𝜎𝑐+1
2 , 𝜽|𝒚) = −
1
2
 log|𝑿′𝐕−𝟏𝑿| + 𝑙𝐹(?̂?(𝜽), σ𝑐+1
2 , 𝜽|𝒚) 
= −
1
2
 log|𝐕| −
1
2
 log|𝑿′𝐕−𝟏𝑿| −
1
2
 (𝒚 − 𝑿𝜷)′𝐕−𝟏(𝒚 − 𝑿𝜷). 
For more details on maximum likelihood and related problems we refer to Harville et al 
(1977) [108]. 
  There are computational methods that can be used to obtain ML, and REML. For 
example Newton-Raphson (NR) and Fisher Scoring algorithms [60]. The NR algorithm is 
an iterative procedure that computes new parameter values 𝜎𝑐+1
2  and 𝜽 from their current 
values [109]. After estimating the variance-covariance matrices 𝜴 and 𝑹, the mixed 
model equations will become [110]: 
[𝑿
′?̂?−1𝑿 𝑿′?̂?−1𝒁
𝒁′?̂?−1𝑿 𝒁′?̂?−1𝒁 + ?̂?−1
] [
?̂?
?̂?
] = [𝑿
′?̂?−1𝒀
𝒁′?̂?−1𝒀
]                                   (4.7) 
 To model biological data, there is often interest in genetic relationships that arise 
from the biology of a situation. A matrix that a counts for whatever genetic relationships 
that exists among individuals is called the relationship matrix or numerator relationship 
matrix; we denote this matrix by (𝐀) as described in Henderson (1976) [111]. Given the 
matrix 𝐀, then, for the variance of the vector of random effects 𝒅 becomes 
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𝑣𝑎𝑟(𝒅) = 𝜎𝑑
2 𝑨 . The use of 𝑨 also extends to the case of multiple traits. For example, for 
two traits, with data vectors  𝒚1, and 𝒚2, we have  
𝑣𝑎𝑟(𝒅) = [
𝜎𝑑1
2 𝑨 𝜎𝑑1𝑑2𝑨
𝜎𝑑2𝑑1𝑨 𝜎𝑑2
2 𝑨
] = [
𝜎𝑑1
2 𝜎𝑑1𝑑2
𝜎𝑑2𝑑1 𝜎𝑑2
2 ]⨂𝑨, 
where 𝒅1 and 𝒅2 are the corresponding vectors of random effects [112]. 
 In genetics the matrices 𝑹 = 𝜎𝜀
2 𝑰 and 𝛀 = 𝜎𝑑
2 𝑨, where the variances 𝜎𝜀
2 and 𝜎𝑑
2 
denote residuals and additive variances. Mammals are genetically related to each other 
and undergoing asexual to produce an offspring that is expected to be correlated, unless 
𝜎𝑑
2 is 0 [113]. Thus, if 𝑑𝑖 is the genetic effect for subject i then 𝑣(𝑑𝑖) = 𝑎𝑖𝑖𝜎𝑑
2 and 
𝑐𝑜𝑣(𝑑𝑖, 𝑑𝑗) = 𝑎𝑖𝑗𝜎𝑑
2, where the values 𝑎𝑖𝑖 and 𝑎𝑖𝑗 can be calculated in different ways 
depending on whether the parents of subject i are known or not. 
 Note that 𝑨 is a positive-definite matrix (unless identical twins or clones are in the 
pedigree, in which case it would be positive semi-definite) [114]. Next section will show 
how to calculate the elements of 𝑨.  
If the matrices 𝑹 and 𝛀 are nonsingular, since 𝑹−1 is an identity matrix, we can rewrite 
the system (4.4) as the following: 
[
𝑿′𝑿 𝑿′𝒁
𝒁′𝑿 𝒁′𝒁 + 𝜹𝑨−1
] [
?̂?
?̂?
] = [
𝑿′𝒚
𝒁′𝒚
], 
where  𝜹 =  
𝜎𝜀
2
𝜎𝑑
2 . Therefore: 
[
?̂?
?̂?
] = [
𝑿′𝑿 𝑿′𝒁
𝒁′𝑿 𝒁′𝒁 + 𝜹𝑨−𝟏
]
−1
[
𝑿′𝒚
𝒁′𝒚
]. 
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4.5 The Numerator Relationship Matrix 
 The numerator relationship (𝑨) is a component of BLUP. When we multiply this 
matrix by the additive genetic variance, it will give the variance-covariance matrix 
among random subject effects. Each element (𝑎𝑖𝑗) is a probability that a random gene 
from a given subject i is identical by descent (IBD) to a gene in the same locus from a 
subject j. In some studies termed the coefficients of kinship [115]. The dimensions of this 
matrix let say we have 𝑞 subjects, then the dimensions will be (𝑞 × 𝑞), also it is 
symmetric. The diagonal element (𝑎𝑖𝑖) represents twice the probability that two gametes 
taken at random from animal i will carry identical alleles by descent. The off-diagonal 
element (𝑎𝑖𝑗) equals the probability that an allele selected randomly from subject i and an 
allele selected randomly from subject j at the same locus are identical alleles by descent 
[116]. The matrix 𝑨 can be computed using a recursive method which was described by 
Henderson (1976). Initially, subjects in the pedigree are coded 1 to n and ordered such 
that parents precede their progeny. The following are rules to calculate the elements of 
this matrix. 
If both parents (f and m) of subject i are known: 
𝑎𝑗𝑖 = a𝑖𝑗 = 0.5(𝑎𝑗𝑓 + 𝑎𝑗𝑚);   𝑗 = 1 𝑡𝑜 (𝑗 − 1)   
𝑎𝑖𝑖 =  1 + 0.5(𝑎𝑓𝑚) 
If only one parent f is known and assumed unrelated to the mate: 
𝑎𝑗𝑖 = 𝑎𝑖𝑗 = 0.5(𝑎𝑓𝑚);   𝑗 = 1 𝑡𝑜 (𝑗 − 1) 
𝑎𝑖𝑖 =  1 
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If both parents are unknown and are assumed unrelated: 
𝑎𝑗𝑖 = 𝑎𝑖𝑗 = 0;   𝑗 = 1 𝑡𝑜 (𝑗 − 1) 
𝑎𝑖𝑖 =  1 
Example: 
The pedigree for a family included seven individuals  
Table 4.1 Pedigree for a family of seven individuals. 
Individual Father Mother 
3 
4 
5 
6 
7 
1 
Unknown 
3 
3 
3 
2 
Unknown 
4 
4 
4 
 
Figure 4.1. Pedigree of seven individuals. 
The calculations to find the numerator relationship matrix for the pedigree table are: 
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𝑎11 =  1                    Both parents of individual 1 are unknown 
𝑎12 = 𝑎21 = 0           both parents of individual 1 or 2 are unknown 
⋮ 
𝑎77 =  1 + 0.5(𝑎𝑓𝑚) = 1 + 0.5(0) = 1     both parents of individual are known 
The A matrix is:  
  
 In this matrix, the diagonal element for subject i (𝑎𝑖𝑖) is equal to 1 + 𝐹𝑖, where 𝐹𝑖 
is called the inbreeding coefficient of subject i [107, 116]. We are going to use the 
numerator relationship matrix 𝑨 in LME and threshold model in next section. The matrix 
𝑨 can also be calculated using pedigreemm package in R (see Appendix D for R code): 
 In our case, we have 𝒀 is a vector which represents breast cancer incidence 
(affected = 1 and normal = 0) with dimension 167×1, and factors namely gender and 
family which will treated as fixed effects, and 𝑿 is design matrix with dimensions 167×5, 
where 5 is the number of levels for fixed effects (male and female and 3 families), 𝜷 is 
5×1 vector of parameters of fixed effects. 𝒁 is 167×167 design matrix associated with the 
vector of genetic effects 𝒅. 






















15.05.05.05.025.025.0
5.015.05.05.025.025.0
5.05.015.05.025.025.0
5.05.05.01000
5.05.05.0015.05.0
25.025.025.005.010
25.025.025.005.001
41 
 
 
 
4.6 The Heritability Coefficient 
 In biological applications, the quantities 𝒅 and 𝜷 in (4.1) denote the genetic and 
environmental effects, respectively. Given that “a central question in biology is whether 
observed variation in a particular trait is due to environmental or biological factors” [57]. 
The heritability coefficient is ℎ2 = 
𝜎𝑑
2
𝜎𝑑
2+𝜎𝜀
2 which represents the proportion of phenotypic 
variance attributed to variation in genotypic values, is a fundamentally important 
quantity. Indeed, linear mixed effects models and inference on the heritability coefficient 
has been applied recently in genome-wide association studies [117, 118]. 
4.7 Genomic Relationships Matrix  
 In linear mixed effects models that include genomic relationships matrix (𝑮) will 
be more accurate than those that use expected relationships from pedigrees matrix. The 
numerator relationship matrix 𝑨 uses the only pedigree information to obtain 
probabilities that gene pairs are identical by descent [116]. But Genomic relationship 
matrix 𝑮 uses the genotypic information to estimate the segment of DNA that two 
individuals share [119].  
 To obtain the matrix, 𝑮, let 𝑴 be the matrix that stipulates which marker alleles 
were inherited by everyone, with dimensions of 𝑛𝑔 ×  𝑠, where 𝑛𝑔 is number of 
individuals with genomic information and  𝑠 is number of SNP’s. 𝑴 has elements from 0, 
1, 2 and 5, representative of homozygote, heterozygote, other homozygote, and missing 
SNP marker, correspondingly. Let 𝑷 be 𝑛𝑔 ×  𝑠 matrix contain frequencies 𝑝𝑖 of the 
second allele at each locus. Therefore, column i of 𝑷 is 2(𝑝𝑖 − 0.5) where 𝑖 = 1,2, … , 𝑆 
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[57, 119]. A 𝑮 is genomic relationship matrix can be found with three different methods. 
First method is: 
𝑮 =
(𝑴 − 𝑷)(𝑴 − 𝑷)′
2∑𝑝𝑖(1 − 𝑝𝑖)
 
Dividing by  2∑𝑝𝑖(1 − 𝑝𝑖) scales matrix 𝑮 to be analogous to the numerator relationship 
matrix  𝑨. In frequency estimates, missing genotypes (coded as 5 in the data) will not be 
included in our calculations. The elements of matrix 𝑴 − 𝑷 set to be zero, which is the 
mean of frequency of missing genotypes, other elements of 𝑴 − 𝑷 will standardized for 
each individual’s proportion of missing genotypes [57]. 
 The genomic inbreeding coefficient for individual 𝑗 is simply 𝐺𝑗𝑗 − 1, and 
genomic relationships between individuals 𝑗 and 𝑘, which are analogous to the 
relationship coefficients of Wright (1922), these coefficients are obtained by dividing 
elements 𝐺𝑗𝑘 by square roots of diagonals 𝐺𝑗𝑗 and 𝐺𝑘𝑘. 
 The second method for obtaining 𝑮 weights markers by reciprocals of their 
expected variance instead of summing expectations across loci and then dividing: 
𝑮 = (𝑴 − 𝑷)𝐃(𝑴 − 𝑷)′, where 𝐃 is diagonal with 𝑫𝑗𝑗 =
1
𝑚[2𝑝𝑖(1−𝑝𝑖)]
. This formula was 
proposed by Amin et al (2007) and Leutenegger et al (2003) [120, 121]. 
 The third method to obtain 𝑮 does not require all ele frequencies and instead 
adjusts for mean homozygosity by regressing 𝑴𝑴′ on 𝑨 and 𝑮 using the following 
model: 
𝑴𝑴′ = 𝛾0𝟏𝟏
′ + 𝛾1𝑨 + 𝑬, 
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Where 𝛾0and 𝛾1 are the intercept and slope, respectably.  
Here is an example showed how to calculate G matrix, suppose we have three individuals 
and two SNP’s and suppose we have encoded AA=2, Aa=1, and aa=0. 
So, matrix M with dimensions 3 × 2. 
𝑴 = [
0 0
0 2
1 2
]   ⇒  [
𝑎𝑎 𝑎𝑎
𝑎𝑎 𝐴𝐴
𝑎𝐴 𝐴𝐴
] 
Also, matrix 𝑷3×2 
Frequency A for locus 1 (SNP1) = ?̂?1 = 
1
6
= 0.16       
Frequency A for locus 2 (SNP2) = ?̂?2 = 
4
6
= 0.667  
First column in P matrix is 2(?̂?1 − 0.5) =  2(0.16 − 0.5) =  −0.68  
Second column in P matrix is 2(?̂?2 − 0.5) =  2(0.667 − 0.5) =  0.32  
𝑷 = [
−0.68 0.32
−0.68 0.32
−0.68 0.32
] 
For the denominator 2∑p𝑗(1 − 𝑝𝑗) = 2 ∗ [0.16 ∗ (1 − 0.16) + 0.667 ∗ (1 − 0.667)] 
       Misztal et al (2009) proposed that it is possible to modify a numerator based 
relationship matrix 𝑨 to a matrix 𝑯 that takes in both pedigree-based relationships and 
genomic information 𝑨∆ [17]: 
𝑯 = 𝑨 + 𝑨∆. 
Let indices 1 and 2 denote ungenotyped and genotyped animals. Then 
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𝑨 = [
𝑨11 𝑨12
𝑨21 𝑨22
], 
𝑯 = [
𝑨11 𝑨12
𝑨21 𝑮
] = 𝑨 + [
0 0
0 𝑮 − 𝑨22
] 
And           𝑨∆ = [
0 0
0 𝑮 − 𝑨22
] 
The inverse of 𝑯 can be calculated as following: 
Let the inverse of matrix 𝑨 be 
𝑨−1 = [𝑨
11 𝑨12
𝑨21 𝑨22
], 
 To derive an inverse function of the combined relationship matrix of [122], using 
the properties of the inverse of a partitioned matrix, identities from 𝑨−1𝑨 = 𝑰 are:     
                                  𝑨11𝑨11 + 𝑨
12𝑨21 = 𝑰                                       𝐴1 
𝑨21𝑨12 + 𝑨
22𝑨22 = 𝑰                                       𝐴2 
𝑨11𝑨12 + 𝑨
12𝑨21 = 𝟎                                       𝐴3 
𝑨21𝑨11 + 𝑨
22𝑨21 = 𝟎, and                                𝐴4 
(𝑨11 + 𝑨12𝑨22
−1𝑨21)
−1 = 𝑨11                             𝐴5  
Using [A1] through [A4], then multiplying the whole-population matrix [18], 
𝑯 = 𝐴 + [
𝑨12𝑨22
−1(𝑮 − 𝑨22)𝑨22
−1𝑨21 𝑨12𝑨22
−1(𝑮 − 𝑨22)
(𝑮 − 𝑨22)𝑨22
−1𝑨21 𝑮 − 𝑨22
] 
                                         𝑯−1 = 𝑨−1 + [
𝟎 𝟎
𝟎 𝑮−1 − 𝑨22
−1] 
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4.8 Threshold model 
 This model is totally flexible. The distribution of the elements of error can be 
taken to be some non-normal (e.g. logistic) distribution. Threshold model can be simply 
extended to multiple responses; some are ordered categorical and others that are 
quantitative. The previous study on the threshold model seems to have been confined 
primarily to the case where the underlying linear model is a fixed-effects model. 
McCullagh (1980) gave a comprehensive discussion of this case. Curnow and Smith 
(1975) reviewed genetic applications of threshold models. Thompson and Baker (1981) 
presented a device, termed a composite link function that allows threshold models to be 
embedded in the framework of the generalized linear models due to Nelder and 
Wedderburn (1972). The threshold model in which it is assumed that the observed 
category is determined by the value of an underlying unobservable continuous response. 
[67]. 
 Suppose we have n indicate the number of observable “individuals”, and 𝜆𝑖 
denote an underlying continuous-response variable associated with the ith of these 
individuals. Take 𝝀 = (𝜆1, 𝜆2, … , 𝜆𝑛)
′.  
Let 𝝀 follows a linear mixed effects model; 
𝝀 = 𝑿𝜷 + 𝒁𝒅 + 𝜺                                                        (4.8) 
matrices 𝑿 and 𝒁 and vectors 𝜷, 𝒅 and 𝜺 were described in model (4.1); the only different 
is the vector 𝝀 which contains 𝑛 × 1 unobserved continuous variable. Give the ordered 
categories numbers from 1 to m. It is assumed that 𝜆𝑖 is unobserved, but we observe the 
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category into which the ith individual falls or the category number 𝑂𝑖, 𝑖 = 1,2, … , 𝑛. 
These categories determined into following relationship: 
𝜏𝑘𝑖−1 < 𝜆𝑖 ≤ 𝜏𝑘𝑖 ⇔ 𝑂𝑖 = 𝑘 ,                                            (4.9) 
where 𝑘 ∈ {1,2, … ,𝑚}, 𝜏0 = −∞, 𝜏𝑚 = +∞ and 𝜏1, … , 𝜏𝑚−1are unknown thresholds 
which partition the real numbers into m categories. Therefore, when the realized value of 
𝜆𝑖 belongs to the 𝑘 interval, the observed values 𝑂𝑖 = 𝑘. 
Following this assumption, the probability-mass function of 𝑂1, …𝑂𝑛 is  
𝑝(𝑂1, … , 𝑂𝑛) = 𝑝𝑟{𝑂𝑖 = 𝑜𝑖(𝑖 = 1,… , 𝑛)} 
= 𝑝𝑟{𝜏𝑜𝑖−1 < 𝜆𝑖 ≤ 𝜏𝑜𝑖 (𝑖 = 1,… , 𝑛)} 
Harville (1984) indicate to this model for the vector 𝒐 = (𝑂1, …𝑂𝑛)
′ of categorical 
responses as the “threshold model”. 
 In implementing the threshold model, there is a request to make inferences about 
various functions of  𝜏1, … , 𝜏𝑚−1, 𝜷 , and sample of the random vector 𝒅 say 𝒅𝑐. In 
special, we need to make inferences about the quantity as following: 
𝑝𝑘,𝑘′ = p𝑟{𝜏𝑘 < 𝑥
′𝜷 + 𝑧′𝒅 + 𝜀 ≤ 𝜏𝑘′ |𝒅 = 𝒅𝑐}                               (4.10) 
where 𝑘 < 𝑘′, 𝑥 and 𝑧 are specified vectors, and 𝜀 is distributed 𝑁(0, 𝜎2) and 
independent on 𝒅. The best choice of  and 𝑧 , which represents the condition probability 
when (𝒅 = 𝒅𝑐) that an (𝑛 + 1) individual (which follows the same model as the 𝑛 
observable individuals) will belong to one of the categories 𝑘 + 1,… , 𝑘′.  
Note that we can re-express the inequality (4.10) as the following: 
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𝜏𝑘𝑖−1 < 𝜆𝑖 ≤ 𝜏𝑘𝑖  
(𝜏𝑘−1 − 𝜏1)/𝜎 < 𝑊𝑖 ≤ (𝜏𝑘 − 𝜏1)/𝜎                                   (4.11) 
Where 𝑊𝑖 = (𝜆𝑖 − 𝜏1)/𝜎, 𝑖 = 1,2, … , 𝑛, 𝑘 = 1,2, … ,𝑚.  
In matrices notations if we have 𝒘 = (𝑊1,𝑊2, … ,𝑊𝑛)
′ and using vector of ones 1, we 
can write; 
𝒘 = (𝟏, 𝑿) [
−𝜎−1𝜏1
−𝜎−1𝜷
] + 𝒁(𝜎−1𝒅) + 𝜎−1𝜺                                       (4.12) 
Therefore, the threshold model can be reformulated in terms of a second threshold model 
whose underlying continuous response variables correspond to (𝜆𝑖 − 𝜏1)/𝜎, 𝑖 =
1,2, … , 𝑛, whose boundaries correspond to (𝜏𝑘 − 𝜏1)/𝜎 , 𝑘 = 1,2, … ,𝑚 − 1, and whose 
vectors of ‘fixed’, ‘random’ and ‘residual’ effects correspond  to 𝜎−1(−𝜏1, 𝜷
′) to 𝜎−1𝒅, 
and to 𝜎−1𝜺, respectively. In the latter, the threshold model, the residual variance equals 
1, the first boundary point equals 0. 
From now, we assume that 𝜎 = 1 and 𝜏1 = 0, also the first column of 𝑿 equals 𝟏. While 
these assumptions are met, we refer to the threshold model as the 'standardized threshold 
model' [67]. If we suppose that 𝝀 is observed, we could use Henderson's Best linear 
unbiased prediction (BLUP) procedure to estimate 𝑥′𝜷 + 𝑧′𝒅. The BLUP would be 
𝑥′?̃? + 𝑧′?̃? where ?̃? and ?̃?  denote any solution to the system of linear equations, 
[
𝑿′𝑿 𝑿′𝒁
𝒁′𝑿 𝒁′𝒁 + 𝛀−𝟏
] [
?̃?
?̃?
] = [
𝑿′𝝀
𝒁′𝝀
] 
There is one way to obtain the mixed model equations and hence at the BLUP, that is 
finding values of 𝜷 and 𝒅 that maximize 
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𝜙𝑁+𝑞 ([
𝝀
𝜷
] ; [
𝑿𝜷
𝟎
] , [
𝚺 𝒁𝛀
𝛀𝒁′ 𝒁′𝒁
]) =  𝜙𝑁(𝝀;𝑿𝜷 + 𝒁𝒅𝑐, 𝐼)𝜙𝑞(𝒅𝑐; 𝟎, 𝛀) 
= 𝜙𝑞(𝒅𝑐; 𝟎, 𝛀) ∏𝜙𝑁
𝑛
𝑖=1
(𝝀𝑖 − 𝑥𝑖
′𝜷 − 𝑧𝑖
′𝒅𝑐),                             (4.13)  
 where 𝑥𝑖
′ and 𝑧𝑖
′ represent the ith rows of 𝑿 and 𝒁, respectively. Note that (4.13) is the 
joint probability density function of 𝝀 and 𝒅.  
Now let us apply to the standardized threshold model (𝝀 is unobserved) an approach 
analogous to the maximization (4.12). 
𝜓(𝑜1, 𝑜2, … , 𝑜𝑛; 𝝉, 𝜷, 𝒅𝑐) =  ∏ ∫ 𝜙(𝝀𝑖 − 𝑥𝑖
′𝜷 − 𝑧𝑖
′𝒅𝑐)
𝜏𝑜𝑖
𝜏𝑜𝑖−1
𝑛
𝑖=1
 𝑑𝝀𝑖 
= ∏{Φ(𝜏𝑜𝑖 − 𝑥𝑖
′𝜷 − 𝑧𝑖
′𝒅𝑐) − Φ(𝜏𝑜𝑖−1 − 𝑥𝑖
′𝜷 − 𝑧𝑖
′𝒅𝑐)}
𝑛
𝑖=1
.            (4.14) 
This procedure consists of estimating 𝒘′𝝉 − 𝑥𝑖
′𝜷 − 𝑧𝑖
′𝒅𝑐 by 𝒘
′?̂? − 𝑥𝑖
′?̂? − 𝑧𝑖
′?̂?𝑐, and ?̂? =
(?̂?2, ?̂?3, … , ?̂?𝑚−1), ?̂? and ?̂?𝑐 denote any values of 𝝉, 𝜷 and 𝒅𝑐 that maximize 
𝜓(𝑂1, 𝑂2, … , 𝑂𝑛; 𝝉, 𝜷, 𝒅𝑐)𝜙𝑞(𝒅𝑐; 𝟎, 𝛀)                                   (4.15) 
We consider the problem of computing ?̂? , ?̂? and ?̂?𝑐 that maximize the function (4.15). 
Given that 𝜔′ = [𝝉′, 𝜷′, 𝒅𝑐
′], Gianola and Foulley (1983) proceeded to find the estimator 
?̂? that maximizes the log of the density 𝐿(𝜔). They therefore provided the following 
non-linear iterative system of equations based on the first and second derivatives, 
assuming a normal distribution, to obtain solutions for Δ𝝉, Δ𝜷 and 𝚫𝒅𝑐 
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[
𝑸 𝑳′𝑿 𝑳′𝒁
𝑿′𝑳 𝐗′𝑻𝑿 𝑿′𝑻𝒁
𝒁′𝑳 𝒁′𝑻𝑿 𝒁′𝑻𝒁 + 𝛀−𝟏
] [
Δ𝝉
Δ𝜷
𝚫𝒅𝑐
] = [
𝑷
𝑿′𝑽
𝒁′𝑽 − 𝛀−𝟏𝚫𝒅𝑐
]                    (4.16) 
The calculation of some of these matrices involves 𝑝𝑖𝑘, which defines the probability of a 
response being observed in category k assuming a normal distribution of the ith row.  
𝑝𝑖𝑘 =  Φ(𝜏𝑘 − 𝑥𝑖
′𝜷 − 𝑧𝑖
′𝒅𝑐) − Φ(𝜏𝑘−1 − 𝑥𝑖
′𝜷 − 𝑧𝑖
′𝒅𝑐) 
This distribution is a function of the distance between 𝑥𝑖
′𝜷 − 𝑧𝑖
′𝒅𝑐 and the threshold, 
Likewise, the height of the normal curve at 𝜏𝑘 under the conditions of the ith row 
becomes:  
𝜙𝑖𝑘 =  𝜙(𝜏𝑘 − 𝑥𝑖
′𝜷 − 𝑧𝑖
′𝒅𝑐) 
To compute the various matrices and vectors in (10.3): 
𝑉𝑖 = ∑ 𝑛𝑖𝑘
𝑚
𝑘=1
(
ϕ𝑖𝑘−1 − 𝜙𝑖𝑘
𝑝𝑖𝑘
) 
Where 𝑛𝑖𝑘 is the number of counts in category k of response in row i, and for the 
elements of the matrix 𝑻, which is a weighting factor, are computed as: 
𝑇𝑖𝑖 = ∑ 𝑛𝑖.
𝑚
𝑘=1
(
𝜙𝑖𝑘−1 − 𝜙𝑖𝑘
𝑝𝑖𝑘
) 
And  𝑛𝑖. = ∑ 𝑛𝑖𝑘
𝑚
𝑘=1   
The matrix 𝑸 is an (m-1) by (m-1) banded matrix and the diagonal elements are 
calculated as: 
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𝑞𝑘𝑘 = ∑𝑛𝑖.
𝑚
𝑖=1
(
𝑝𝑖𝑘 − 𝑝𝑖(𝑘+1)
𝑝𝑖𝑘𝑝𝑖(𝑘+1)
)𝜙𝑖𝑘
2 , 𝑘 = 1,… , (𝑚 − 1) 
and for the off-diagonal elements are: 
𝑞(𝑘+1)𝑘 = −∑𝑛𝑖.
𝑚
𝑖=1
𝜙𝑖(𝑘+1)𝜙𝑖𝑘
𝑝𝑖(𝑘+1)
, for 𝑘 = 1,… , (𝑚 − 2) 
and  𝑞(𝑘+1)𝑘 = 𝑞𝑘(𝑘+1). 
The matrix 𝑳 is of order 𝑛 by (m − 1) and its elements are calculated as: 
𝑙𝑖𝑘 = − 𝑛i.𝜙𝑖𝑘 (
𝜙𝑖𝑘 − 𝜙𝑖(𝑘−1)
𝑝𝑖𝑘
−
𝜙𝑖(𝑘+1)− 𝜙𝑖𝑘
𝑝𝑖(𝑘+1)
) 
The elements of the vector 𝑷 are: 
𝑝𝑘 = {∑ [
𝑛𝑖𝑘
𝑝𝑖𝑘
−
𝑛𝑖(𝑘+1)
𝑝𝑖(𝑘+1)
]𝑛𝑖=1 𝜙𝑖𝑘} ; 𝑘 = 1,… ,𝑚 − 1. 
The matrices L and P are then substituted in the system of  equation (4.16) [107]. 
4.9 Gibbs Sampling Method 
 This is a numerical integration method based on all possible conditional posterior 
distributions. It was first implemented by Geman and Geman (1984). In this method, the 
marginal posterior distributions generate random drawings by taking iterative samples 
[107]. Wang et al (1993) used Gibbs sampling to estimate variance components in 
univariate linear mixed effects model [124].  
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4.9.1 Prior and Posterior Distributions 
 Suppose we have the following univariate linear mixed effects model: 
𝒀 = 𝑿𝜷 + 𝒁𝒅 + 𝜺 
Where 𝒀 is a vector of observations with dimension 𝑛 × 1; 𝜷 is a vector of fixed effects 
with dimension p×1; 𝒅 is a vector of random effects with dimension 𝑞 ×  1; 𝜺 is a vector 
of errors; 𝑿 and 𝒁 are design matrices for the fixed and random effects with dimensions 
𝑛 × 𝑝 and 𝑛 × 𝑞 respectively. The conditional distribution that generates the vector 𝒀 is: 
𝒀|𝜷, 𝒅, 𝜎𝑒
2~𝑁(𝑿𝜷 + 𝒁𝒅,𝑹𝜎𝑒
2) 
The matrix 𝑹 here assumed to be identity with 𝑛 × 𝑛 dimension and 𝜎𝑒
2 is residual 
variance. 
 Bayesian analysis required to determine prior distributions to the unidentified 
parameters. Nonetheless, the prior distributions of 𝜷, 𝒅, 𝜎𝑒
2 and 𝜎𝑑
2 are needed to fulfill 
the Bayesian condition of the model [124]. Commonly a flat, improper prior distribution 
was used for vector 𝜷, as follows:      
P(𝜷) ~ constant                                                  (4.17) 
Also, a multivariate normal distribution (MVN) was used for 𝒅: 
𝒅 ~MVN(0, 𝑨𝜎𝑑
2)                                                (4.18) 
Where 𝑨 is a numerator relationship matrix. In addition, for variance components 𝜎𝑒
2 and 
𝜎𝑑
2 the priors are the scaled inverted Chi-squared distribution form: 
𝑝(𝜎𝑒
2|𝑣𝑒 , 𝑠𝑒
2) ∝ (𝜎𝑒
2)
−𝑣𝑒
2
−1 exp(
−1
2
𝑣𝑒𝑠𝑒
2/𝜎𝑒
2)                           (4.19) 
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And 
𝑝(𝜎𝑑
2|𝑣𝑑 , 𝑠𝑑
2) ∝ (𝜎𝑑
2)
−𝑣𝑑
2
−1 exp(
−1
2
𝑣𝑑𝑠𝑑
2/𝜎𝑑
2)                           (4.20) 
 The parameters are degrees of belief 𝑣𝑒 , 𝑣𝑑, and 𝑠𝑒
2, 𝑠𝑑
2 for (4.19) and (4.20) 
respectively. The assumption for the degrees of belief parameters 𝑣𝑒 and 𝑣𝑑 equal to zero 
to find the improper priors: 
𝑝(𝜎𝑒
2) ∝ (𝜎𝑒
2)−1 ;  𝑝(𝜎𝑑
2) ∝ (𝜎𝑑
2)−1                                        (4.21) 
The proper uniform prior is: 
𝑝(𝜎2) ∝ {𝑘  0 ≤ 𝜎
2 ≤ 𝜎2𝑚𝑎𝑥
0 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
 
 The common technique for calculating the conditional densities required for 
Gibbs sampling is to use the conditional independence in models (4.17-4.21) to write the 
joint posterior density as: 
𝑝(𝜷, 𝒅, 𝜎𝑒
2, 𝜎𝑑
2|𝐲)  ∝
1
(𝜎𝑒
2)
𝑛
2
+1
 exp (−
1
2𝜎𝑒
2 (𝐲 − 𝑿𝜷 − 𝒁𝒅)
′(𝐲 − 𝑿𝜷 − 𝒁𝒅)) 
×
1
(𝜎𝑑
2)
𝑞
2
+1
 exp (−
1
2𝜎𝑑
2 𝒅
′𝑨−1𝒅)                                   (4.22) 
 In Gibbs sampling method, the full conditional posterior for each parameter is 
needed; the scaled inverted Chi-square is the full conditional posterior for residual 
variance 𝜎𝑒
2 which given by: 
𝑝(𝜎𝑒
2|𝜷, 𝒅, 𝜎𝑑
2, 𝐲)  ∝  
𝑝(𝜎𝑒
2, 𝜷, 𝒅, 𝜎𝑑
2
|𝐲) 
∫ 𝑝(𝜎𝑒
2, 𝜷, 𝒅, 𝜎𝑑
2
|𝐲) 𝑑𝜎𝑒2
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∝
1
(𝜎𝑒2)
𝑛
2
+1
exp (−
1
2𝜎𝑒2
(𝐲 − 𝑿𝜷 − 𝒁𝒅)′(𝐲 − 𝑿𝜷 − 𝒁𝒅))
1
(𝜎𝑑
2)
𝑞
2
+1
 exp (−
1
2𝜎𝑑
2 𝒅
′𝑨−1𝒅)
1
(𝜎𝑑
2)
𝑞
2
+1
 exp (−
1
2𝜎𝑑
2 𝒅
′𝑨−1𝒅)∫
1
(𝜎𝑒2)
𝑛
2
+1
exp (−
1
2𝜎𝑒2
(𝐲 − 𝑿𝜷 − 𝒁𝒅)′(𝐲 − 𝑿𝜷 − 𝒁𝒅))𝑑𝜎𝑒2
 
∝
1
(𝜎𝑒2)
𝑛
2
+1
exp (−
1
2𝜎𝑒2
(𝐲 − 𝑿𝜷 − 𝒁𝒅)′(𝐲 − 𝑿𝜷 − 𝒁𝒅))
∫
1
(𝜎𝑒2)
𝑛
2
+1
exp (−
1
2𝜎𝑒2
(𝐲 − 𝑿𝜷 − 𝒁𝒅)′(𝐲 − 𝑿𝜷 − 𝒁𝒅))𝑑𝜎𝑒2
 
Because the denominator is constant with respect to 𝜎𝑒
2 then: 
𝑝(𝜎𝑒
2|𝜷, 𝒅, 𝜎𝑑
2, 𝐲)  ∝ (𝜎𝑒
2)
−𝑛
2
−1exp (−
1
2𝜎𝑒
2 (𝐲 − 𝑿𝜷 − 𝒁𝒅)
′(𝐲 − 𝑿𝜷 − 𝒁𝒅))             (4.23) 
Where the parameters are 𝑣𝑒 = 𝑛 and 𝑠𝑒
2 = (𝐲 − 𝑿𝜷 − 𝒁𝒅)′(𝐲 − 𝑿𝜷 − 𝒁𝒅)/𝑛. Each of 
the Gibbs conditionals can be computed in this manner [125]. So, the full conditional 
posterior for additive variance 𝜎𝑑
2 is the scaled inverted Chi-squared: 
𝑝(𝜎𝑑
2|𝜷, 𝒅, 𝜎𝑒
2, 𝐲)  ∝ (𝜎𝑑
2)
−𝑞
2
−1exp (−
1
2𝜎𝑑
2 𝒅
′𝑨−𝟏𝒅)                                 (4.24) 
With the parameters 𝑣𝑒 = 𝑞 and 𝑠𝑒
2 = 𝒅′𝑨−𝟏𝒅/𝑞. 
The full condition posterior of  𝜷 is: 
𝜷| 𝒅, 𝜎𝑒
2, 𝜎𝑑
2, 𝐲 ~ 𝑁[?̃?, (𝑿′𝑿)−1𝜎𝑒
2]                                (4.25) 
Where ?̃? = (𝑿′𝑿)−1𝑿′(𝐲 − 𝒁𝒅) 
For the random vector 𝒅: 
𝒅| 𝜷, 𝜎𝑒
2, 𝜎𝑑
2, 𝐲 ~ 𝑁[?̃?, (𝒁′𝒁 + 𝑨−1
𝜎𝑒
2
𝜎𝑑
2)
−1
𝜎𝑒
2]                                (4.26) 
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Where ?̃? = (𝒁′𝒁 + 𝑨−1
𝜎𝑒
2
𝜎𝑑
2)
−1
𝒁′(𝐲 − 𝑿𝜷 − 𝒁𝒅) 
After defining these four posterior distributions, implementing Gibbs sampling steps can 
be shown below: 
i. setting arbitrary initial values of  𝜷, 𝒅, 𝜎𝑒
2, 𝜎𝑑
2; 
ii. generate 𝜎𝑒
2 from (4.23), and update it; 
iii. generate 𝜎𝑑
2 from (4.24), and update it; 
iv. generate 𝒅 from (4.26), and update it; 
v. generate 𝜷 from (4.25), and update it; 
vi. repeat steps (ii to v) k times, and update the values each time, where k denoted the 
length of Gibbs chain (iteration). Let (𝜎𝑒
2)(𝑘), (𝜎𝑑
2)(𝑘), (𝒅)(𝑘) and (𝜷)(𝑘) are the 
sample points with kth iteration. Then: 
vii. repeat steps (i-vi) 𝑚 times, to get 𝑚 Gibbs samples. Then we have: 
(𝜎𝑒
2)1
(𝑘)
, (𝜎𝑒
2)2
(𝑘)
, … , (𝜎𝑒
2)𝑚
(𝑘)
~𝑝(𝜎𝑒
2|𝐲) 
(𝜎𝑑
2)1
(𝑘)
, (𝜎𝑑
2)2
(𝑘)
, … , (𝜎𝑑
2)𝑚
(𝑘)
~𝑝(𝜎𝑑
2|𝐲) 
(𝒅)1
(𝑘)
, (𝒅)2
(𝑘)
, … , (𝒅)𝑚
(𝑘)
~𝑝(𝒅|𝐲) 
(𝜷)1
(𝑘)
, (𝜷)2
(𝑘)
, … , (𝜷)𝑚
(𝑘)
~𝑝(𝜷|𝐲) 
Since the interest is to estimate the variance components 𝜎𝑒
2 and 𝜎𝑑
2, we will not monitor 
vectors 𝒅 and 𝜷 [124].  
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 After getting samples, and as noted by Casella and George (1992) and Gelfand 
and Smith (1990), the estimator of the marginal density of 𝜎𝑒
2 is: 
?̂?(𝜎𝑒
2|𝒚) =
1
𝑚
∑𝑝(𝜎𝑒
2|(𝜷)𝑗
(𝑘), (𝒅)𝑗
(𝑘), (𝜎𝑑
2)𝑗
(𝑘),
𝑚
𝑗=1
𝒚) 
Similarly, the estimator of the marginal density of 𝜎𝑑
2 is: 
?̂?(𝜎𝑑
2|𝒚) =
1
𝑚
∑𝑝(𝜎𝑑
2|(𝜷)𝑗
(𝑘), (𝒅)𝑗
(𝑘),
𝑚
𝑗=1
𝒚) 
 For threshold model; the response variable 𝑂𝑖 for each individual takes on two 
possible values 1 or 0; The variable is the expression of latent continuous variable 𝜆𝑖; this 
liability of individual 𝑖. The variable 𝑂𝑖 takes 1 if 𝜆𝑖 exceeds an unknown fixed threshold 
𝜏 and 0 otherwise. The variable 𝜆𝑖 is distributed normal with mean 𝜃 and variance 1. 
Hence: 
𝜆𝑖|𝜃~𝑁(𝑤𝑖
′𝜃, 1) 
Where 𝜃′ = (𝜷′,𝒅′) and 𝜷, 𝒅 as defined in model (4.8), also 𝑤𝑖
′  is a row incidence vector 
related to individual 𝑖. The conditional posterior of thresholds and liabilities are uniforms 
and truncated normals, respectively. The remaining parameters (𝜷, 𝒅, 𝜎𝑒
2, 𝜎𝑑
2 ) are the 
same in linear mixed effect model [87]. 
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For giving 𝜃, the conditional distributions of 𝜆𝑖 are independent. Therefore, the joint 
density is given by 
𝑝(𝝀|𝜃) = ∏ 𝜙𝜆𝑖(𝑤𝑖
′𝜃, 1) = 𝜙𝜆(𝐖𝛉, 𝐈)
𝑛
𝑖=1                             (4.27) 
Where 𝜙𝜆 (.) is a normal density, also in (4.27) put 𝐖𝛉 = 𝑿𝜷 + 𝒁𝒅 + 𝜺. However, given 
the model, we have: 
𝑝(𝑂𝑖 = 1|𝜃, 𝜏) = 𝑝(𝜆𝑖 > 𝜏|𝛉, τ) = ∫ 𝜙(𝑥)
∞
𝜏−𝑤𝑖
′𝜃
𝑑𝑥 = Φ(−(𝜏 − 𝑤𝑖
′𝜃))       (4.28) 
Where Φ (.) is the cumulative distribution function of a standard normal. We can set the 
constant τ to 0. So the model (4.28) can be write as: 
𝑝(𝑂𝑖 = 1|𝜃) = Φ(𝑤𝑖
′𝜃)                                          (4.29) 
Distribution of 𝜆𝑖 conditional on 𝜃 and on 𝑂𝑖 = 𝑜𝑖 follows a truncated normal 
distribution. So for 𝑜𝑖 = 1: 
𝑝(𝜆𝑖|𝜃, 𝑂𝑖 = 1) =
𝜙𝜆𝑖(𝑤𝑖
′𝜃,1)
Φ(𝑤𝑖
′𝜃)
 1(𝜆𝑖 > 0)                                   (4.30) 
Where 1 (𝑋 ∈ 𝑅) is the indicator function that takes 1 if  𝑋 is contained in the set 𝑅, and 
0 otherwise [87]. For 𝑜𝑖 = 0 , the density is  
𝑝(𝜆𝑖|𝜃, 𝑂𝑖 = 0) =
𝜙𝜆𝑖(𝑤𝑖
′𝜃,1)
Φ(−𝑤𝑖
′𝜃)
 1(𝜆𝑖 ≤ 0)                                   (4.31) 
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4.10 Predicting SNP effects 
           Let the random effects vector 𝒅 be decomposed into those for genotyped (𝒅𝑔) and 
ungenotyped (𝒅𝑛) individuals. The random effects of genotyped individuals are a 
function of SNP effects 𝒈: 
𝒅𝑔 = 𝒁𝑔𝒈 
SNP effects can be projected using genomic liability 𝒅 ̂, 𝑫 which is a diagonal matrix of 
weights for the variances of SNPs. 𝒁𝑔 is a matrix linking the genotype of each locus per 
the following: 
?̂? = 𝑫𝒁𝒈
`[𝒁𝒈𝑫𝒁𝒈
`]−𝟏?̂?𝒈 
Dimensions: ?̂? is 𝑆 ×  1, D is 𝑆 ×  𝑆 and 𝒅𝑔 ̂  is 𝑛𝑔  ×  1. This is the best predictor for 
SNP effects [102].  
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CHAPTER 5 
MULTITRAITS MODELS 
5.1 Introduction 
 The excellent method to evaluate the subjects on different traits is a multiple trait 
analysis, because it considers the relationship between these traits. Analysis of multiple 
traits includes the simultaneous evaluation of subjects for more than one trait and makes 
use of the genetic and phenotypic correlations between the traits. Henderson and Quaas 
(1976) applied the first BLUP in multiple traits. We will present the multivariate BLUP 
(MBLUP) in this chapter and give examples in its application [107]. 
5.2 Multiple Trait Model 
 The method is based on an extension of Henderson's method for practical of 
relatives records in single trait model. Furthermore, the main advantage of MBLUP is 
that the increase of accuracy. This accuracy depends on the absolute difference between 
the residual and genetic correlations between the traits. The larger the enhancement in 
efficiency is due the larger of differences in these correlations. 
 Suppose we have 𝑛 related jubects each with records on 𝑡 traits, for each of the 
traits we have a stack of the univariate models as following: 
[
𝒀1
⋮
𝒀𝑡
] = [
𝑿1 𝟎 … 𝟎
𝟎 𝑿2 … 𝟎
⋮ ⋮ ⋱ ⋮
𝟎 𝟎 ⋯ 𝑿𝑡
] [
𝑩1
⋮
𝑩𝑞
] + [
𝒁1 𝟎 … 𝟎
𝟎 𝒁2 … 𝟎
⋮ ⋮ ⋱ ⋮
𝟎 𝟎 ⋯ 𝒁𝑡
] [
𝒅1
⋮
𝒅𝑡
] + [
𝒆1
⋮
𝒆𝑡
] 
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Where 𝒀𝑖 is avector of the response observations for trait 𝑖, 𝑩𝑖 and 𝒅𝑖 are vectors of fixed 
and random effects for the trait 𝑖, 𝒆𝑖 is vector of residuals effects for trait 𝑖, and matrices 
𝑿𝑖 and 𝒁𝑖 are design matrices related to fixed and random effects, respectively [107]. 
5.3 Equal Design Matrices 
 If all traits are affected by the same fixed effect and records of all subjects are 
taken for all traits, then the same design matrices 𝑿 and 𝒁 are use for all traits. 
Forexample, we have two traits and for each trait we can write the model as follows: 
For the first trait: 
𝒀𝟏 = 𝑿𝟏𝜷𝟏 + 𝒁𝟏𝒅𝟏 + 𝜺𝟏 
The second trait is: 
𝒀𝟐 = 𝑿𝟐𝜷𝟐 + 𝒁𝟐𝒅𝟐 + 𝜺𝟐 
If we order the subjects with respect traits, we could write the multivariate model in the 
following form: 
[
𝒀1
𝒀2
] = [
𝑿1 𝟎
𝟎 𝑿2
] [
𝑩1
𝑩2
] + [
𝒁1 𝟎
𝟎 𝒁2
] [
𝒅1
𝒅2
] + [
𝒆1
𝒆2
]                                        (5.1) 
It is assumed that the variance of random effects 𝒅𝑖 and residuals 𝒆𝑖 given by: 
𝑉𝑎𝑟 [
𝒅1
𝒅2
𝒆1
𝒆2
] = [
𝑔11𝑨 𝑔12𝑨 0 0
𝑔21𝑨 𝑔22𝑨 0 0
0 0 𝑟11𝑰 𝑟12𝑰
0 0 𝑟21𝑰 𝑟22𝑰
] 
Where 𝑮 = [
𝑔11 𝑔12
𝑔21 𝑔22
] is additive variance-covariance matrix for random effects. The 
elements of matrix 𝑮 are; 𝑔11 is additive variance for direct effect of trait 1; 𝑔12 = 𝑔21 is 
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additive convariance between traits 1 nad 2; 𝑔22 is additive variance for direct effect of 
trait 2; 𝑨 is the numerator relationship matrix (see section 4.5); 𝑹 = [
𝑟11 𝑟12
𝑟21 𝑟22
] is 
variance-convariance matrix of residuals. 
The heritability for trait i can be calculated using the following formula [128]: 
ℎ𝑖
2 =
𝑔𝑖𝑖
𝑔𝑖𝑖 + 𝑟𝑖𝑖
 
To solve the multivariate model (5.1) we can use mixed model equations system as the 
following: 
[
𝑿′𝑹−1𝑿 𝑿′𝑹−1𝒁
𝒁′𝑹−1𝑿 𝒁′𝑹−1𝒁 + 𝑨−1⨂ 𝑮−1
] [
?̂?
?̂?
] = [
𝑿′𝑹−1𝒚
𝒁′𝑹−1𝒚
]                                      (5.2) 
Where 
𝑿 = [
𝑿1 𝟎
𝟎 𝑿2
], ?̂? = [
?̂?1
?̂?2
], 𝒁 = [
𝒁1 𝟎
𝟎 𝒁2
], ?̂? = [
?̂?1
?̂?2
] and 𝒚 = [
𝒚1
𝒚2
] 
We can rewrite MME for multivariate model with two traits as follows: 
[
 
 
 
 
𝑿1
′ 𝑹11𝑿1 𝑿1
′ 𝑹12𝑿2 𝑿1
′ 𝑹11𝒁1 𝑿1
′ 𝑹12𝒁2
𝑿2
′ 𝑹12𝑿1 𝑿2
′ 𝑹22𝑿2 𝑿2
′ 𝑹21𝒁1 𝑿2
′ 𝑹22𝒁2
𝒁1
′ 𝑹11𝑿1 𝒁1
′ 𝑹12𝑿2 𝒁1
′ 𝑹11𝒁1 + 𝑨
−1𝑔11 𝒁1
′ 𝑹12𝒁2 + 𝑨
−1𝑔12
𝒁2
′ 𝑹21𝑿1 𝒁2
′ 𝑹22𝑿2 𝒁2
′ 𝑹21𝒁1 + 𝑨
−1𝑔21 𝒁2
′ 𝑹22𝒁2 + 𝑨
−1𝑔22]
 
 
 
 
[
 
 
 
 
?̂?1
?̂?2
?̂?1
?̂?2]
 
 
 
 
=
[
 
 
 
 
𝑿1
′ 𝑹11𝒚1 + 𝑿1
′ 𝑹12𝒚2
𝑿2
′ 𝑹21𝒚1 + 𝑿2
′ 𝑹22𝒚2
𝒁1
′ 𝑹11𝒚1 + 𝒁1
′ 𝑹12𝒚2
𝒁2
′ 𝑹21𝒚1 + 𝒁2
′ 𝑹22𝒚2]
 
 
 
 
 
61 
 
 
 
Where 𝑔𝑖𝑗 are the elments of the inverse of the additive variance-covariance matrix, 𝑮−1. 
Note that if the two traits are uncorrelated then 𝑹12 and 𝑔12 will be zero. In this case the 
matirces in the equation above reduce two the single trait model [107]. 
[
 
 
 
 
𝑿1
′ 𝑟11𝑿1 0 𝑿1
′ 𝑟11𝒁1 0
0 𝑿2
′ 𝑟22𝑿2 0 𝑿2
′ 𝑟22𝒁2
𝒁1
′ 𝑟11𝑿1 0 𝒁1
′ 𝑟11𝒁1 + 𝑨
−1𝑔11 0
0 𝒁2
′ 𝑟22𝑿2 0 𝒁2
′ 𝑟22𝒁2 + 𝑨
−1𝑔22]
 
 
 
 
[
 
 
 
 
?̂?1
?̂?2
?̂?1
?̂?2]
 
 
 
 
=
[
 
 
 
 
𝑿1
′ 𝑟11𝒚1
𝑿2
′ 𝑟22𝒚2
𝒁1
′ 𝑟11𝒚1
𝒁2
′ 𝑟22𝒚2]
 
 
 
 
 
Example: 
The data below are the pre-weaning gain (WWG) and postweaning gain (PWG) for five 
beef calves, we interested to estimate the fixed effect (sex) and random effect (breeding 
values) for all animals: 
Table 5.1. Pre-weaning gain and post-weaning gain (kg) for five beef calves. 
Calf Sex Sire Dam WWG PWG 
4 Male 1 - 4.5 6.8 
5 Female 3 2 2.9 5.0 
6 Female 1 2 3.9 6.8 
7 Male 4 5 3.5 6.0 
8 Male 3 6 5.0 7.5 
 
Using MBLUP analysis. Assume that the additive genetic covariance 𝑮 Matrix is: 
𝑮 =
𝑊𝑊𝐺
𝑃𝑊𝐺
[
20 18
18 40
] 
And the residual covariance matrix is:  
𝑹 =
𝑊𝑊𝐺
𝑃𝑊𝐺
[
40 11
𝑟21 30
] 
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Since the matrices are too large, the MME have not presented. The solutions of the 
system given below: 
Table 5.2 Solutions of multiple traits model. 
Effects WWG PWG 
Sex 
1 
 
4.361 
 
6.800 
2 3.397 5.880 
Animal 
1 
 
0.151 
 
0.280 
2 −0.015 −0.008 
3 −0.078 −0.170 
4 −0.010 −0.013 
5 −0.270 −0.478 
6 0.276 0.517 
7 −0.316 −0.479 
8 0.244 0.392 
 
Where for fixed effect, 1 = male and 2 = female. 
5.4 Unequal Design Matrices 
 In multivariate analysis, the model called unequal (unbalanced) if traits are 
affected through different fixed or random effects. For example, the multiple traits model 
of yields in different locations. However, in this case we can apply Henderson et al 
(1976) for evaluation [128]. 
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Example: 
We have fat yield in each parity as different traits shown in the table below: 
Cow Sire Dam HYS1 HYS2 FAT1 FAT2 
4 1 2 1 1 201 280 
5 3 2 1 2 150 200 
6 1 5 2 1 160 190 
7 3 4 1 1 180 250 
8 1 7 2 2 285 300 
 
For parity 1 and 2 the herd-year-season are HYS1 and HYS2, respectively; FAT1 and 
FAT2 fat yield in parity 1 and 2. To estimate the breeding values (FAT1 and FA2), 
assume the genetic and environmental parameters are: 
𝑮 = [
35 28
28 30
]     and        𝑹 = [
65 27
𝑟21 70
] 
For the inverses are: 
𝑮−𝟏 = [
0.113 −0.105
−0.105 0.132
]     and        𝑹 = [
0.018 −0.007
−0.007 0.017
] 
[
 
 
 
 
?̂?1
?̂?2
?̂?1
?̂?2]
 
 
 
 
=
[
 
 
 
 
𝑿1
′ 𝑹11𝑿1 𝑿1
′ 𝑹12𝑿2 𝑿1
′ 𝑹11𝒁1 𝑿1
′ 𝑹12𝒁2
𝑿2
′ 𝑹12𝑿1 𝑿2
′ 𝑹22𝑿2 𝑿2
′ 𝑹21𝒁1 𝑿2
′ 𝑹22𝒁2
𝒁1
′ 𝑹11𝑿1 𝒁1
′ 𝑹12𝑿2 𝒁1
′ 𝑹11𝒁1 + 𝑨
−1𝑔11 𝒁1
′ 𝑹12𝒁2 + 𝑨
−1𝑔12
𝒁2
′ 𝑹21𝑿1 𝒁2
′ 𝑹22𝑿2 𝒁2
′ 𝑹21𝒁1 + 𝑨
−1𝑔21 𝒁2
′ 𝑹22𝒁2 + 𝑨
−1𝑔22]
 
 
 
 
−1
×
[
 
 
 
 
𝑿1
′ 𝑹11𝒚1 + 𝑿1
′ 𝑹12𝒚2
𝑿2
′ 𝑹21𝒚1 + 𝑿2
′ 𝑹22𝒚2
𝒁1
′ 𝑹11𝒚1 + 𝒁1
′ 𝑹12𝒚2
𝒁2
′ 𝑹21𝒚1 + 𝒁2
′ 𝑹22𝒚2]
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The matrix 𝑿1 relates HYS1 effect and 𝑿2 relates to HYS2 effect. The transposes of 
these unequal matrices are: 
𝑿1
′ = [
1 1 0 1 0
0 1 0 0 1
]               and           𝑿2
′ = [
1 0 1 1 0
0 1 0 0 1
] 
The solutions of MME are: 
Effects FAT1 FAT2 
HYS 
1 
 
175.7 
 
243.2 
2 219.6 240.6 
Animal 
1 
 
8.969 
 
8.840 
2 −2.999 −2.777 
3 −5.970 −6.063 
4 11.754 11.658 
5 −16.253 −15.824 
6 −17.314 −15.719 
7 8.690 8.138 
8 22.702 20.931 
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CHAPTER 6 
ANALYSIS 
6.1 Introduction 
 The variance components and heritability estimates for familial breast cancer 
incidence were calculated with a threshold model using the recorded binary observations 
linked to the probit function (transformation). This chapter will present these programs 
and the steps used for analysis. Four programs in Fortran 90/95 and R software were 
used to analyze the data. All graphs in this chapter were created using R software, in 
order to show the distributions and the autocorrelation functions of variance components 
and heritability estimates. We estimated heritability using two methods; first, we used the 
MCMCglmm Package in R for phenotypic data only and second, we included genomic 
data (SNP) using the THRGIBBS1F90 program. 
6.2 The MCMCglmm R Package 
For the binary phenotype variable, the model is defined on an underlying latent variable: 
𝝀 = 𝑿𝜷 + 𝒁𝒅 + 𝜺                                                     (6.1) 
Where 𝑿 and 𝒁 are design matrices relating to fixed and random effects, respectively. 
These matrices have associated parameter vectors 𝜷 and 𝒅, while 𝜺 is a residual vector. 
The distribution of vectors 𝒅 and 𝜺 are assumed to be multivariate normal distribution as: 
𝒅~𝑁(𝟎, 𝑮) and 𝜺~𝑁(𝟎, 𝑹). The matrices 𝑮 and 𝑹 are (co)variances of the random 
effects and residuals, respectively. The structure form of 𝑮 in MCMCglmm is: 
𝑮 = (𝑽1⨂𝑨1)⨁(𝑽2⨂𝑨2)⨁…                                          (6.2) 
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Typically, the (co)variance matrices (𝑽) are low-dimensional and the structured matrices 
are (𝑨) high dimensional. The terms are separated by a direct sum (⨁) as component 
terms and each component term is formed through the Kronecker product (⨂). So if we 
have two component terms, we can write matrix 𝑮 as: 
𝑮 = [
(𝑽1⨂𝑨1) 𝟎
𝟎 (𝑽2⨂𝑨2)
] 
By the same manner, we can get 𝑹:  
 𝑹 = (𝑽𝑒1⨂𝑰1)⨁(𝑽𝑒2⨂𝑰2)⨁…                                          (6.3) 
Where 𝑽𝑒1, 𝑽𝑒2 are residual variances and 𝑰1, 𝑰2 are identity matrices [129]. 
To fit the binary data 𝑦𝑖 for one trait, we use a probit link and a Bernoulli distribution: 
𝑦𝑖 = 𝐵(𝑝𝑟𝑜𝑝𝑡
−1(𝜆𝑖)) 
Since we want to calculate heritability for the model (6.1), it is necessary to take into 
account a supplementary source of variance coming from the probit link.  
ℎ̂2 =
𝜎𝑑
2
𝜎𝑑
2 + 𝜎𝑒2 + 1
 
This is justified by the fact that, to be strictly equivalent to a threshold model (where y is 
1 if 𝜆 > 0), we need to include the “variance” of the link transformation into the total 
variance, which is 1 for a probit link [130]. 
 In MCMCglmm, the prior distribution of the (co)variances is an inverse-Wishart 
and a normal prior for the fixed effect. For a single variance component, an inverse-
Gamma distribution with parameters nu and v (𝑖𝑛𝑣𝑒𝑟𝑠𝑒 − 𝐺𝑎𝑚𝑚𝑎 (
𝑛𝑢
2
,
𝑛𝑢×𝑣
2
)) is a 
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common choice. The possible set of parameters would be nu=0.002 and v=1, which is 
actually 𝑖𝑛𝑣𝑒𝑟𝑠𝑒 − 𝐺𝑎𝑚𝑚𝑎(0.001,0.001)[131] because 𝛼 =
𝑛𝑢
2
 , 𝛽 =
𝑛𝑢 𝑉
2
. In a binary 
variable, the residual variance (𝑉𝑅) will be fixed to 1 and an estimate additive 
variance (𝑉𝐺). Also, when we want to estimate the heritability of binary data, it is advised 
to use chi-square prior [132]. 
 Our estimation of heritability is 0.03947 using 𝑖𝑛𝑣𝑒𝑟𝑠𝑒 − 𝐺𝑎𝑚𝑚𝑎(0.001,0.001) 
which is the common prior. Using chi-square with 1 degree of freedom as prior, 
heritability is 0.3369; refer to the R code in Appendix E. The diagnostic of the results 
from both priors is described as follows.  
 Before we consider our estimation as a final estimation, we need to check the 
convergence and autocorrelation of samples. In MCMCglmm output, there are two main 
components (model$Sol and model$VCV) where Sol is the posterior distribution 
solution, including fixed effects, and VCV is a posterior distribution of (co)variance 
matrices. First, let us look at the trace of samples from 𝑖𝑛𝑣𝑒𝑟𝑠𝑒 − 𝐺𝑎𝑚𝑚𝑎(0.001,0.001) 
prior (Figure 6.1 and Figure 6.2). 
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Figure 6.1 Trace of the fixed effects using inverse-Gamma (0.001, 0.001). 
 
As we can see for each graph of the samples (Figures 6.1 and 6.2), the values are widely 
spread. While the values in the graphs of samples (Figures 6.3 and 6.4) are spread 
(fluctuated) in a small range, these samples were generated using chi-square with 1 
degree of freedom as prior.   
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Figure 6.2 Trace of the variance components inverse-Gamma (0.001, 0.001). 
Also, little autocorrelation is found in the samples that were generated from 𝑖𝑛𝑣𝑒𝑟𝑠𝑒 −
𝐺𝑎𝑚𝑚𝑎(0.001,0.001), especially in the family, animal and units (Table 1.1). However, 
the autocorrelation is reasonable for the sample of additive variance generated from Chi-
square (6.2). Note that we fixed the residual variance to 1 in this prior (Figure 6.3 and 
Figure 6.4). 
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Figure 6.3 Trace of the fixed effects using chi-square. 
 
  
Table 1.1 The autocorrelation of samples from 𝑖𝑛𝑣𝑒𝑟𝑠𝑒 − 𝐺𝑎𝑚𝑚𝑎. 
 Intercept sex Family Animal      
Lag 0 1.000000 1.000000 1.000000 1.000000 
Lag 40 0.107780 0.227881 0.581473 0.782403 
Lag 200 0.077046 0.168276 0.520311 0.531336 
Lag 400 0.045379 0.141118 0.433896 0.335605 
Lag 2000 0.032968 0.038969 0.125210 0.024426 
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Table 6.2 The autocorrelation of samples from Chi-square. 
 Intercept sex Family Animal      
Lag 0 1.000000 1.000000 1.000000 1.000000 
Lag 40 0.171016 0.072454 0.007925 0.438784 
Lag 200 0.006327 0.004607 -0.010548 0.043452 
Lag 400 0.011712 0.015504 0.001981 -0.004161 
Lag 2000 -0.008358 0.004110 -0.013991 0.010373 
 
 
Figure 6.4. Trace of the variance component using chi-square. 
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In MCMCglmm, the convergence is often very fast. Therefore, we used the Heidelberg 
stationarity test to see if the convergence is reasonable; if the p-value exceeds 0.05, that 
means the sample is from a stationary distribution. 
Table 6.3 Convergence test of samples generated from inverse-Gamma. 
 Stationarity test Start iteration p-value 
animal passed 1 0.513 
Units passed 1 0.399 
 
 
Table 6.4 Convergence test of sample generated from Chi-square. 
 Stationarity test Start iteration p-value 
animal passed 1 0.435   
6.3 BLUPF90 in Fortran 90/95  
 The analysis in this research was also completed using BLUPF90 in Fortran 
90/95. These programs were originally developed as exercises for a class taught by 
Ignacy Misztal at the University of Georgia [133]. Gradually, they have been upgraded 
and improved by many contributors. This a family of programs for mixed-models 
computations. The programs can execute data conditioning, estimate variances using 
several methods, compute BLUP for very large data sets, calculate approximate accuracy, 
and use SNP data for improved accuracy of breeding values for GWAS studies [134]. 
The programs have been designed with three goals:  
i. Flexibility to support a large set of models found in animal breeding applications. 
ii. Software simplicity to abate errors and enable modifications. 
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iii. Productivity at the algorithmic level. 
The four programs used in this study are RENUMF90, THRGIBBSxF90, 
POSTGIBBSF90 and POSTGSF90 [133].  
a. RENUMF90 
 This is a program for renumbering in the BLUPF90 family of programs. It 
supports multiple traits, dissimilar effects per trait, alphanumeric and numeric 
fields. The program provides data statistics, preforms comprehensive pedigree 
checking, and supports unknown parent groups. 
b. THRGIBBS1F90 
 This program performs a Gibbs sampler for threshold-linear mixed effect 
models involving multiple categorical and linear variables. The original program 
THRGIBBSF90 was composed by DeukHwan Lee in 2001, and rewritten by 
Shogo Tsuruta in 2004. This program should be used after the renumbering 
program RENUMF90. 
c. POSTGIBBSF90 
 This program was designed to calculate posterior means, standard 
deviation and diagnosis of convergence. The program reads gibbs_samples and 
fort.99 files from Gibbs sampling (THRGIBBS1F90) programs. The output files 
from this program are postgibbs_samples, postmean, postsd and postout. 
d. POSTGSF90 
 This program is used to obtain the prediction of SNP effects. The output 
files from this program are snp_sol, chrsnp, chrsnpvar and snp_pred (the second 
file contains the values of SNP effects used in Manhattan plots). 
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6.3.1 The THRGIBBS1F90 
 The joint posterior distribution was estimated using the MCMC method based on 
Gibbs sampling with the THRGIBBS1F90 software [134]. The number of iterations is 
250000, with 50000 samples discarded as burn-in for convergence, with the remaining 
samples being thinned using intervals of 20 samples. Ten thousand (10000) samples were 
stored and used to calculate the posterior features of interest, such as posterior means and 
standard deviations. The derived variance components and heritability estimates for 
familial breast cancer incidence are shown in Table 6.5. 
Table 6.5 Variance components and heritability estimates. 
  Additive Effect Residuals variance Heritability 
Mean 0.0590174 0.1471117 0.2812776 
SD 0.02835517 0.02496394 0.1166282 
Confidence Interval 2.5%    97.5% 
0.0147    0.1225 
2.5%    97.5% 
0.1019     0.19910 
2.5%      97.5% 
0.0765    0.5187 
 
 The heritability coefficient is an estimate of the amount of variation in a 
phenotypic trait in a population due to genetic variation among individuals in that 
population. Here it is 28% variation in the response variable, as explained by genetic 
variations (SNPs). 
6.4 Plots of Estimators 
 If we look at the histogram graphs (see Figure 6.5), each graph clearly shows 
more data around the average, where the highest "bump" is located, indicating this as 
“symmetrical." This is a good sign that the averages (for each estimator) are 
approximately in the center of the data. 
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Figure 6.5 Histogram with density of the variances and heritability estimates. 
6.5 History and Autocorrelation Function Plots 
The series of estimated values show a consistent trend, as noted in Figure 6.6. The series 
of additive variance estimates fluctuate around the same value, which is approximately 
0.059. Likewise, the same behavior is seen for the other two estimated values, where the 
residuals variance fluctuates around 0.147 and heritability is close to 0.28. Furthermore, 
the autocorrelation function (ACF) measures the correlation between pairs of random 
variables. The optimal plot of ACF decays reasonably rapidly to zero, either from above 
or below. We can see that all ACFs (Figure 6.7) have decayed to zero before lag 10, 
which indicates that the series of samples are independent.  
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Figure 6.6 Sample series plots of the variances and heritability estimates. 
 
 
Figure 6.7 Autocorrelation functions of the variances and heritability estimates. 
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 It is essential to check the convergence to determine whether we are as close to 
the actual value as possible. The burn-in value, at 50000, was sufficient to reach 
convergence. Also, to avoid an autocorrelation issue, we used a thinning interval of 20 
and noted that the autocorrelation function went to zero after a few lags, which was good. 
6.6 Manhattan Plot 
GWAS analysis typically reports a visualization of genome-wide association of 
SNPs using a Manhattan plot. The SNP effects are displayed as their absolute values (y-
axis) against SNP location (x-axis: chromosomes and SNP positions). The higher dots 
represent high SNP effects at a given position associated with familial breast cancer [96]. 
In this context, gene mapping based on a Manhattan plot (Figure 6.8) showed that there are 
some areas on the genome (chromosomes 1, 2, 4, 8, 14 and 16) that may include candidate 
genes associated with breast cancer incidence and susceptibility.  
 
Figure 6.8 Manhattan Plot of SNPs effects. 
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In the Manhattan plot (Figure 6.8), we do not use thresholds, or p-values, because 
two problems may arise when we use a single SNP regression. First, thousands of tests will 
be run and SNP effects will be over-estimated. Second, it is difficult to define a genomic 
region with the true mutation [135, 136]. To avoid these two problems, we fitted SNP 
effects simultaneously.  
The 20 markers with the highest effects are shown in Table . These SNPs explained 
more than 3.5% of the genetic variance, which indicates that this group of SNPs, and hence 
their genes, are highly associated with the incidence of this disease.  
Table 6.6 Ordered SNP effects with locations. 
No SNP Effects CHROM POS GENE 
1 4.371465 2 223793480 ACSL3 
2 4.349453 4 187534542 FAT1 
3 4.198865 1 225611661 LBR 
4 3.800145 1 150999863 PRUNE 
5 3.787771 4 187534375 FAT1 
6 3.736460 4 187535169 FAT1 
7 3.661992 8 27147716 TRIM35 
8 3.661992 8 27147939 TRIM35 
9 3.653323 2 44547909 SLC3A1 
10 3.649030 2 224569668 PREPL 
11 3.647262 14 50094913 NEMF/ DNAAF2 
12 3.641489 2 44547574 SLC3A1 
13 3.641489 2 44550290 PREPL 
14 3.641489 2 44570804 PREPL 
15 3.641489 2 44617324 CAMKMT 
16 3.617063 16 71668800 MARVELD3 
17 3.544095 2 217123958 MARCH4 
18 3.51585 2 44550233 PREPL 
19 3.498177 2 178936373 PDE11A 
20 3.496521 4 187077393 FAM149A 
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CHAPTER 7 
DISCUSSION AND CONCLUSION 
Among various types of cancer, breast cancer has been reported as the second most 
deadly cancer in the world. In addition, patients who have been diagnosed as positive for 
this disease face the issue that no treatment is currently available to prevent or reduce the 
occurrence of this cancer [4]. For this reason, more consideration is being given to genomic 
studies that are based on advanced statistical models and methodologies to track the cause 
of this disease, with promising progress being achieved [26]. Finding a genetic component, 
as well as a genomic region, that could be associated with breast cancer will facilitate the 
diagnosis of those most likely to be infected with breast cancer in the future. This does not 
just raise caution, but will also allow for early treatment, which may lead to preventing the 
disease from progressing to advanced stages. In this study, we estimated the heritability of 
breast cancer incidence based on the presence of breast cancer in 167 people, of which 22 
had genomic information. Since the response variable was binary, a threshold model was 
used [21]. In order to maximize the usage of this small data set, we decided to combine 
both the pedigree data and the genomic data in one analysis [17]. This approach has been 
widely used with accurate results [18]. The challenge was to scale the genomic data to the 
pedigree data, so the two sources of information can be reasonably combined. 
The heritability estimate for breast cancer incidence obtained in this study indicates 
that genetic tracking can be used to investigate the probability of the incidence of the 
disease. Furthermore, a genetic component becomes a simple indicator that a genomic 
region on the DNA is associated with the incidence of this disease. For any trait with a non-
zero heritability, the genetic effects must be located somewhere on the chromosomes [137]. 
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The heritability estimates showed that genetics plays a key role in the incidence of this type 
of cancer. In other words, there is a genetic component that can be further investigated to 
determine the genes or genomic regions that might be associated with breast cancer. It is 
then a matter of locating that genetic effect and genotyping the appropriate DNA. 
Since the heritability estimate was higher than zero, we decided to apply a GWAS, 
which will predict the effect of each marker (SNP) we have in the genomic data and provide 
the extent of the genetic variation that can be explained by markers. The GWAS revealed 
that several genes, with small effects for each, might be responsible for breast cancer 
incidence. Specifically, SNPs on chromosomes 1, 2, 4, 8, 14 and 16 could be related to the 
incidence of the disease. Some of these results confirm findings from other similar studies 
[138]. Seven genes were mentioned in previous studies as related to breast cancer. The 
ACSL3 (acyl-CoA synthetase long chain family member 3) gene may be one that enhances 
the amount of cytotoxicity if it gets suppressed, while SREBPs are responsible for aberrant 
proliferation of breast cancer cells [139]. FAT1 (FAT atypical cadherin 1) is one of the 
FAT family of genes which are vital to suppress cancer cells based on their ability of 
homozygous deletion; they can also help to determine oncogenic status [140]. The gene 
PRUNE (prune exopolyphosphatase 1) is related to metastasis in breast cancer; when h-
PRUNE gets suppressed by dipyridamole, the connection with nm23-H1 increases, which 
leads to increasing the cellular movement in the metastasis process [141]. TRIM35 
(tripartite motif containing 35) cooperates in the process of the formation and increase in 
the size of cell cancers [142]. SLC3A1 (solute carrier family 3 member 1) is crucial because 
it promotes the cysteine uptake and antioxidant N-acetylcysteine. Also it is considered 
therapeutic in the treatment of breast cancer [143]. A strong relationship has been noted 
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between SNPs and breast cancer risk, with one of these SNPs called "re8410," located in 
the PREPL (prolyl endopeptidase-like) gene [144]. Gene MARVELD3 (MARVEL domain 
containing 3) is very helpful for paracellular ion connections [145]. 
We also found new seven genes that could be related to breast cancer. These genes 
are: LBR (lamin B receptor); NEMF (nuclear export mediator factor); DNAAF2 (dynein 
axonemal assembly factor 2); CAMKMT (calmodulin-lysine N-methyltransferase); 
MARCH4 (membrane associated ring-CH-type finger 4); PDE11A (phosphodiesterase 
11A) and FAM149A (family with sequence similarity 149 member A).  
The results of this study demonstrate that breast cancer is a complex disease, 
probably controlled by many genes with small effects. Finding genes that show major 
effects is uncommon for disease traits. Such traits are usually influenced by many 
biological components and function factors controlled by a large number of genes. 
Furthermore, disease traits are affected by environmental factors. 
 The main limitation of this work was the sample size. Collecting a larger sample, 
as well as pedigree information in humans, is not an easy task. Further studies depend upon 
the availability of larger datasets, which may then reveal more information on this complex 
trait. It may also help to reduce the number of genes potentially associated with breast 
cancer. Also, including the SNPs that have higher effects through fine mapping and 
pathway analysis may uncover more knowledge about breast cancer incidence and help in 
determining various ways to reduce and prevent the disease in the future [146]. 
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Future works: 
1) Estimating heritability coefficient using Aguilar et al (2010) approach in R software. 
2) Increase the size of data by adding family or more available to get more knowledge 
about breast cancer.  
3) Making check these SNPs that have higher effects in pathway analysis to see if they 
biological related to familial breast cancer. 
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APPENDIX A 
ID SEX DAD MAM Y family 
1 M NA NA 0 1 
2 F NA NA 0 1 
3 M NA NA 0 1 
4 F 1 2 1 1 
5 F 1 2 0 1 
6 F 1 2 0 1 
7 M 1 2 0 1 
8 F NA NA 0 1 
9 M NA NA 1 1 
10 F 3 4 1 1 
11 F 3 4 0 1 
12 F 3 4 0 1 
13 F 3 4 1 1 
14 M NA NA 0 1 
15 M 3 4 1 1 
16 F NA NA 0 1 
17 M 3 4 1 1 
18 F NA 5 0 1 
19 M NA 5 1 1 
20 M NA 6 0 1 
21 F NA 6 0 1 
22 F NA 6 0 1 
23 F 7 8 0 1 
24 F 7 8 1 1 
25 M 7 8 0 1 
26 M 7 8 0 1 
27 F 7 8 1 1 
28 M 7 8 0 1 
29 F 7 8 0 1 
30 F 7 8 1 1 
31 M 7 8 0 1 
32 M 7 8 0 1 
33 F 9 10 1 1 
34 M 9 10 1 1 
35 M 9 10 1 1 
36 F 9 10 1 1 
37 F 0 12 0 1 
38 M 0 12 0 1 
39 M 14 13 0 1 
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40 F 14 13 0 1 
41 M 15 16 1 1 
42 F 15 16 0 1 
43 F 15 16 1 1 
44 M 15 16 0 1 
45 M 15 16 0 1 
46 M 15 16 0 1 
47 F 17 NA 0 1 
48 M 17 NA 0 1 
49 M NA 18 0 1 
50 M 19 NA 0 1 
51 F NA 21 0 1 
52 M NA 23 0 1 
53 M 25 24 0 1 
54 F 25 24 1 1 
55 M 28 27 0 1 
56 F 28 27 0 1 
57 M 28 27 0 1 
58 F NA 29 0 1 
59 F NA 29 0 1 
60 F NA 29 0 1 
61 F 31 30 0 1 
62 F 31 30 0 1 
63 M NA NA 0 2 
64 F NA NA 0 2 
65 M 63 64 1 2 
66 F NA NA 0 2 
67 F 63 64 1 2 
68 M NA NA 0 2 
69 F 63 64 0 2 
70 M NA NA 0 2 
71 F 63 64 1 2 
72 M NA NA 0 2 
73 F 63 64 1 2 
74 M NA NA 0 2 
75 M 63 64 0 2 
76 F NA NA 0 2 
77 M 63 64 1 2 
78 F NA NA 0 2 
79 F 65 66 0 2 
80 M 65 66 0 2 
81 M 65 66 0 2 
82 M 68 67 0 2 
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83 M 68 67 0 2 
84 M 68 67 0 2 
85 F 68 67 0 2 
86 F 70 69 0 2 
87 F 70 69 1 2 
88 F 70 69 1 2 
89 M 70 69 0 2 
90 F 72 71 0 2 
91 M 74 73 0 2 
92 F 74 73 0 2 
93 M 74 73 0 2 
94 F 75 76 0 2 
95 M 75 76 0 2 
96 M 77 78 0 2 
97 M NA NA 0 3 
98 F NA NA 0 3 
99 M NA NA 0 3 
100 F 97 98 1 3 
101 F 97 98 0 3 
102 M 97 98 1 3 
103 F NA NA 1 3 
104 F 97 98 1 3 
105 M NA NA 0 3 
106 M 97 98 0 3 
107 F NA NA 0 3 
108 M 97 98 0 3 
109 F 99 100 0 3 
110 M NA NA 0 3 
111 M 99 100 1 3 
112 M 99 100 1 3 
113 F 99 100 1 3 
114 M 99 100 0 3 
115 F 99 100 0 3 
116 F 99 100 1 3 
117 M 99 100 0 3 
118 F 99 100 1 3 
119 M NA NA 1 3 
120 F 99 100 0 3 
121 M 99 100 0 3 
122 M 99 100 0 3 
123 F 99 100 1 3 
124 F 102 103 0 3 
125 M 102 103 0 3 
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126 M 105 104 0 3 
127 M 106 107 0 3 
128 M 106 107 1 3 
129 M 108 NA 0 3 
130 F NA NA 0 3 
131 M 108 NA 0 3 
132 F 108 NA 0 3 
133 F 108 NA 0 3 
134 F 108 NA 0 3 
135 F 110 109 0 3 
136 F 110 109 0 3 
137 F 110 109 0 3 
138 F 110 109 0 3 
139 F 110 109 1 3 
140 F 119 118 1 3 
141 M 119 118 0 3 
142 M 119 118 0 3 
143 F 119 118 0 3 
144 F 119 118 1 3 
145 M 119 118 0 3 
146 M 119 118 0 3 
147 M 119 118 0 3 
148 M 119 118 0 3 
149 F NA 124 0 3 
150 M NA 124 0 3 
151 F 125 NA 0 3 
152 M 125 NA 0 3 
153 F 129 130 0 3 
154 M 129 130 0 3 
155 F 129 130 1 3 
156 F 129 130 1 3 
157 F 129 130 1 3 
158 F 129 130 1 3 
159 F 129 130 0 3 
160 F 131 NA 0 3 
161 M 131 NA 0 3 
162 F NA 132 0 3 
163 F NA 132 0 3 
164 F NA 132 0 3 
165 F NA 133 0 3 
166 M NA 133 0 3 
167 F NA 134 0 3 
 
96 
 
 
 
APPENDIX B 
bowtie2 mapping statistics 
Family_1 
 
 
97 
 
 
 
 
 
  
98 
 
 
 
 
 
  
99 
 
 
 
 
 
 
  
100 
 
 
 
  Family_2 
 
 
  
101 
 
 
 
 
 
  
102 
 
 
 
 
 
  
103 
 
 
 
 
 
  
104 
 
 
 
Family_3 
 
 
  
105 
 
 
 
 
 
  
106 
 
 
 
 
 
  
107 
 
 
 
APPENDIX C 
 
 
 
 
108 
 
 
 
 
 
 
109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
 
 
 
 
 
111 
 
 
 
 
 
 
112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
113 
 
 
 
 
 
 
114 
 
 
 
 
 
 
115 
 
 
 
APPENDIX  D 
 
 
 
  
116 
 
 
 
APPENDIX  E 
 
 
 
 
  
117 
 
 
 
 
 
 
